

PRESIDENT'S COLUMN

Establishing Clinical Pharmacist Core Practice Competencies

Several pharmacy organizations have recently addressed the need to establish competency in our profession among students, residents, and practitioners. In the past 3 months, the American College of Clinical Pharmacy (ACCP) has released two new guidelines: the updated ACCP guideline on clinical pharmacist competencies (www.accp.com/docs/positions/guidelines/Competencies_Final_2.25.17.pdf) and the accompanying ACCP template for evaluating clinical pharmacists (www.accp.com/docs/positions/guidelines/Lee_3.3.17.pdf). Both papers are available on our website and will soon be published in *Pharmacotherapy*. These guidelines update the 2008 paper on clinical pharmacist competencies and the original 1993 "Template for the Evaluation of a Clinical Pharmacist" and were written by the 2016 ACCP Certification Affairs and Clinical Practice Affairs committees, respectively.

The "ACCP Clinical Pharmacist Competencies" paper includes six core competencies necessary for providing clinical pharmacy services in team-based, patient-centered care settings: direct patient care, pharmacotherapy knowledge, systems-based care and population health, communication, professionalism, and continuing professional development. These domains are intended to ensure clinical pharmacists' competency to provide comprehensive medication management as defined in the 2014 ACCP Standards of Practice (www.accp.com/docs/positions/guidelines/StndrsPracClinPharm_Pharmaco8-14.pdf) and are in general alignment with the core competencies for practicing physicians established by the Accreditation Council for Graduate Medical Education (ACGME; www.ecfmg.org/echo/acgme-core-competencies.html).

The updated "ACCP Template for Evaluating a Clinical Pharmacist" relies on assessment of tasks associated with the six core clinical pharmacist competencies. The authors include criteria for evaluating several optional tasks as well, such as serving in leadership roles, conducting pharmacotherapy-related research, and educating health care professionals. The template design includes suggestions for evaluating performance in each domain and provides a column for users to insert their own criteria to define success within the clinical pharmacist's specific practice environment.

The timing of these new ACCP guidelines coincides with that of several other pharmacy or health care-related competency-based documents. In 2016, the Interprofessional Education Collaborative released an update of its Core Competencies for Interprofessional Collaborative Practice (https://ipecollaborative.org/uploads/IPEC-2016-Updated-Core-Competencies-Report_final_release_.PDF). The document includes four competency areas: working with individuals of other professions to maintain a climate of respect and shared values; using the knowledge of the individual's own role as well as the roles of other professions to assess and direct the health care needs of patients and promote and advance the health of populations; communicating with patients, families, communities, and other professionals to support a team approach to the promotion of health and prevention and treatment of disease; and applying relationship-building values and the principles of team dynamics to plan, deliver, and evaluate patient- and population-centered care. This document, designed for use in interprofessional education as well as clinical practice, is further divided into subcompetencies and serves as a useful tool for either individual or team-based assessment. It may also be useful as a supplement to the ACCP clinical pharmacist evaluation template when the team as a whole needs to be evaluated to add context to clinical pharmacist performance.

Other recent guidelines include those of the American Society of Health-System Pharmacists, which released the latest revision of the Accreditation Standard for Postgraduate Year One (PGY1) Pharmacy Residency Programs in 2016 (<https://www.ashp.org/professional-development/residency-information/residency-program-directors/residency-accreditation/accreditation-standards-for-pgy1-pharmacy-residencies>). This is the latest update of the major revision in the 2014 standard. An updated standard for postgraduate year two (PGY2) programs was released in 2015, with competency areas, goals, and objectives for programs in critical care, oncology, pediatrics, and psychiatry released in 2016. Documents for the remaining PGY2 programs are expected to be released later this year. These new standards and accompanying competency areas, goals, and objectives were developed to better reflect current pharmacy practice, with greater emphasis on team-based practice and process improvement, further streamlining of the evaluation process, and provision of increased consistency across programs. Although these residency competencies don't currently align closely with the ACCP or ACGME competencies, they reflect iterative progress toward better defining the patient care-related learning outcomes achieved during postgraduate training.

In late 2016, the American Association of Colleges of Pharmacy (AACP) also released a new document, "Core Entrustable Professional Activities for New Pharmacy Graduates" (www.aacp.org/governance/council/faculties/Documents/oreEntrustableProfessionalActivitiesforNew-PharmacyGraduates.pdf). This document was designed to reflect similar efforts in academic medicine to define the activities that can be entrusted to new medical school graduates in 2014 by the Association of American Medical Colleges (AAMC), "Core Entrustable Professional Activities for Entering Residency: Curriculum Developers' Guide" (<https://members.aamc.org/eweb/upload/Core%20EPA%20Curriculum%20Dev%20Guide.pdf>). Moreover, the AACP entrustable professional activities (EPAs) document for pharmacists aligns with the AAMC EPAs for medical school graduates. The six domains listed in the AACP document are patient care provider, inter-professional team member, population health promoter, information master, practice manager, and self-developer. Although the medicine and pharmacy documents differ, there is considerable agreement within the knowledge, patient care, population health, communication, professionalism, and continued professional development components that contribute to the respective EPAs.

I believe the emphasis on establishing and updating professional competencies is a very positive sign for the pharmacy profession because it reflects our continued professional evolution toward team-based, patient-centered care. Better definitions and evaluations of our clinical competence will no doubt contribute to improved patient medication-related outcomes.



PRNS PREPARE FOR ELECTIONS

PRNs Prepare for Elections

Introduction

It is time for the PRNs to determine who will serve as officers in the coming year. If you are interested in being a PRN officer or in nominating someone, please contact your PRN's chair.

Election Process

The Nominations Committee will consist of at least two individuals appointed by the PRN's chair. These individuals may be the PRN's current elected officers. Those who are on a PRN's Nominations Committee will be ineligible to run for office in that PRN's election that year. The Nominations Committee should prepare a slate of candidates and shall provide information related to election procedures to each candidate. The Nominations Committee shall also provide a timeline and list of expected duties.

When possible, two or three candidates for each office shall be up for election. If only one candidate can be identified, an election will still be held, with voters given the option of identifying a write-in candidate. When there are more than three possible candidates, the PRN's Nominations Committee will be responsible for narrowing the slate to three candidates. The Nominations Committee will obtain a brief (250 words) biographical sketch or candidate statement from each candidate.

Voting

As in previous years, PRN elections will be held online. PRN members will receive an e-mail from ACCP that outlines the voting procedure. Members will use their log-in and password to access the ACCP website. Each member will then be able to access the ballot for each PRN of which he or she is a current member.

2017 Election Timetable

PRN call for nominations	March 2017
Submission of slates and candidate biographies to ACCP	June 9, 2017
Electronic balloting opens	August 14, 2017
Committee contact notified of results	August 17, 2017
Nominations Committee notifies all candidates of election results	August 23, 2017 (within 10 days of the election)
27 ACCP staff notifies new officers of meeting date and time at the ACCP Annual Meeting	September 2017

As the election nears, members should review their e-mail messages and the ACCP website for further news about online voting.

NEW ACCP ANNUAL MEETING TEMPLATE



New Meeting Template for the 2017 ACCP Annual Meeting

Join us October 7–10, in Phoenix, Arizona, for the 2017 ACCP Annual Meeting. Beginning in 2017, the

American College of Clinical Pharmacy (ACCP) will debut a new Annual Meeting template, reconfigured to better meet the needs of the College’s diverse membership. The first full day of programming will begin Saturday, October 7, and the conference will conclude one day earlier, Tuesday, October 10.

The new meeting template offers members the quality, cutting-edge clinical education programming that ACCP has always consistently delivered. This year’s educational sessions will address a variety of issues facing the clinical pharmacy profession, including the opioid epidemic, antibiotic resistance, mobile health technology in the treatment of the modern-day patient, and the long-term effects of newer agents for diabetes. ACCP will also continue to offer specialized clinical programming, including Practice and Research Network (PRN) focus sessions, Academy programming, advocacy initiatives, and scientific poster sessions. Student participants can learn how to “Emerge from the Crowd” as residency candidates, and residents and fellows will find programming designed to meet their specific needs as they transition into new practitioners.

New this year, ACCP professional recruitment opportunities will be expanded to include a forum for new practitioners. The newly configured Professional Placement Forum will offer a separate recruitment session for new

practitioners as well as sessions dedicated to members seeking residency or fellowship training. Participants will be able to meet face-to-face with employers offering a variety of postgraduate training and entry-level positions.

Practitioners seeking Board of Pharmacy Specialties recertification credit will have ample opportunity to earn recertification credit during the Annual Meeting, with the Clinical Reasoning Series in Ambulatory Care, Critical Care, and Pharmacotherapy or the BCOP Clinical Sessions cosponsored by ACCP and the American Society of Health-System Pharmacists.

Registration for the 2017 ACCP Annual Meeting will open June 1. Early-bird registration rates will be available until September 1. Please visit www.accp.com after June 1 for complete Annual Meeting information.

PRN NEWS BRIEFS

Adult Medicine PRN

Members of the AMED PRN work tirelessly to expand the frontiers of clinical pharmacy by improving patient care, conducting research, and providing education in their everyday practices. This is no better demonstrated than by the 95 posters presented by AMED PRN members at the 2016 ACCP Annual Meeting in Hollywood, Florida. These included the AMED PRN Poster of the Year, “Identification of Risk Factors Associated with Urinary Tract Infections Caused by ESBL Organisms in a Community Hospital” (by Tiffany Dickey, Pharm.D.; Victoria Seaton, Pharm.D.; and Bradley Gann, Pharm.D.), which was also a runner-up for ACCP Best Poster Award. Since the Annual Meeting, there has been a flurry of activity in the PRN. In the fall of 2016, the AMED PRN reformed its committee structures to include a merged Internal Affairs Committee and a new External Affairs Committee. The AMED PRN also launched social media sites in November 2016, including a Facebook page (www.facebook.com/accpamedprn) and a Twitter account (@accpamedprn). Follow us and use the hashtag #amedprn! In 2017, we began monthly online journal clubs led by pharmacy practice residents and started a mentorship program for PRN members in their first few years of practice. We are excited about our new programs and activities and are proud of our members’ recent accomplishments (outlined below). We hope you join us in congratulating them!

Promotions

- **Michael D. Novario:** Regional Director of Pharmacy Operations for OSF HealthCare.
- **Mate M. Soric:** Vice Chair, Practice-Based Research, Northeast Ohio Medical University College of Pharmacy.

Grants

- **Sarah L. Anderson:** Project title: Qualitative and Quantitative Assessment of Electronic Examination Implementation. Funding Agency: University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences. Direct costs: \$2175.00.

Awards

- **Mate M. Soric:** American College of Clinical Pharmacy New Clinical Practitioner Award.

Alexandra Vance:

- Navy Pharmacy's Civilian Pharmacist of the Year, October 2016.
- Naval Hospital Jacksonville Senior Civilian Employee of the Year (for 2016), February 2017.

Publications

- **Anderson SL**, Kattappuram R, Marrs JC, Joseph NM. Intentional brodifacoum ingestion. *Am J Med* 2017;130:e27-8.
- **Covert K**, Mardis C, Fleming J, Pilch N, et al. Development of a predictive model for drug-related problems in kidney transplant recipients. *Pharmacotherapy* 2017;37:159-69.
- **D'Angelo RG**, Rincavage M, Tata AL, Millstein LS, Gulati MS, Flurie RW, Gonzales JP. Impact of an antipsychotic discontinuation bundle during transitions of care in critically ill patients. *J Intensive Care Med* 2016 Jan 1. [Epub ahead of print]
- McAuliffe L, O'Gara E, Balaguera H, Lei Y, Mitchell L, **Lancaster JW**. Evaluation of antibiotic management in the reduction of recurrent chronic obstructive pulmonary disease (COPD) exacerbations. *J Acad Hosp Med* 2016;8(2).
- Set J, O'Gara E, Grgurich P, **Lancaster JW**, Lei Y, Craven D. Evaluation of initial antimicrobial management in patients with community-acquired and healthcare-associated pneumonia at a tertiary, teaching hospital. *J Acad Hosp Med* 2016;8(1).
- **Lyon K**, Martello J, Likar E, Regier M. Retrospective cross-sectional pilot study of rifaximin dosing for the prevention of recurrent hepatic encephalopathy. *J Gastroenterol Hepatol* 2017. [Epub ahead of print]
- Anderson SL, Kattappuram R, **Marrs JC**, Joseph NM. Intentional brodifacoum ingestion. *Am J Med* 2017;130:e27-8.
- **McMorris TE**, Smith WJ, Kupiec K, Salvaggio M, Skrepnek GH, Abraham L, Resendez S. Micafungin therapy for symptomatic candiduria in hospitalized patients: a review of 14 cases. *Infect Dis Clin Pract* 2017;25:88-93.

- **Miesner AR**, Lyons W, McLoughlin A. Educating medical residents through podcasts created by PharmD students. *Curr Pharm Teach Learn*. In press.
- **Nisly SA**, Isaacs AN, White C, Chamberlin SM. 24-month pharmacotherapy residency: the what and how behind these programs. *Curr Pharm Teach Learn* 2016;8:796-803.
- **Nisly SA**, Janzen KM, Steuber TD, Trujillo TN. Alumni survey as a quality-improvement tool for defining residency success. *Am J Health Syst Pharm* 2016;73:1722-5.
- Dy-Boarman E, Martin D, **Nisly SA**. Use of a health screening and education event to change student attitudes towards the elderly. *Curr Pharm Teach Learn* 2017;9:101-7.
- **Oung AB**, Saseen J. Do statins reduce the effectiveness of the influenza vaccine? *Evid Based Pract* 2017;20:9.
- **Owens RE**, Snyder HS, Twilla JD, Satapathy SK. Pharmacologic treatment of alcoholic hepatitis: examining outcomes based on disease severity stratification. *J Clin Exp Hepatol* 2016;6:275-81.
- Oliphant CS, **Owens RE**, Bolorunduro OB, Jha SK. Ivabradine: a review of labeled and off-label uses. *Am J Cardiovasc Drugs* 2016;16:337-47.
- **Soric MM**, Moorman JM, Boyle JA, Dengler-Crish CM. Prevalence and predictors of metformin prescribing in adults with type 2 diabetes mellitus: a national cross sectional study. *Pharmacotherapy* 2016;36:715-22.
- Ulbrich TR, Rogers J, **Soric MM**. Top 10 residency application mistakes. *Student Pharmacist* 2016;13:14-5.
- **Wargo KA**. Transitioning from pharmacy practice into administration. *Curr Pharm Teach Learn* 2017. <http://dx.doi.org/10.1016/j.cptl.2017.02.006>.
- American College of Clinical Pharmacy Educational Affairs Committee (Schwinghammer TL, Crannage AJ, Boyce EG, Bradley B, Christensen A, Dunnenberger HM, Fravel M, Gurgle H, Hammond DA, Kwon J, Slain D, **Wargo KA**). The 2016 ACCP Pharmacotherapy Didactic Curriculum Toolkit (ACCP Commentary). *Pharmacotherapy* 2016;36:e189-94.
- Mospan GA, **Wargo KA**. Evaluation of an outpatient 5-day course of levofloxacin in males with a urinary tract infection: a subgroup analysis of a previously published trial. *J Am Board Fam Med* 2016;29:654-62.

- Mospan GA, **Wargo KA**. Researchers' experience with clinical data sharing. *J Am Board Fam Med* 2016;29:805-7.
- **Wietholter JP**. Glaucoma. In: Katz M, Matthias K, Chisholm-Burns MA, eds. *Pharmacotherapy Principles and Practice Study Guide: A Case-Based Care Plan Approach*, 4th ed. New York: McGraw-Hill, 2016:261-3.
- **Wietholter JP**, Coetzee R, Nardella B, Kincaid SE, Slain D. International healthcare experiences: caring while learning and learning while caring. In: *Handbook of Research on Study Abroad Programs and Outbound Mobility*, 1st ed. Hershey, PA: IGI Global, 2016:470-96.
- **Wietholter JP**, Ponte CD, Long DM. The perceived value of clinical pharmacy service provision by pharmacists and physicians: an initial assessment of family medicine and internal medicine providers. *Int J Pharm Pract* 2016.

New ACCP Fellows

- **Sarah A. Nisly**
- **Kurt A. Wargo**
- **Abigail M. Yancey**

Other Notable Achievements

- **Sarah L. Anderson**: Most accessed paper in *Pharmacotherapy* in 2016: "The effect of medical marijuana on migraine headache frequency in an adult population."
- **Kelly Covert**: Assistant Professor of Pharmacy Practice, East Tennessee State University Bill Gatton College of Pharmacy.
- **Jason Lancaster**: Conley M, DiVall M, Gonyeau M, **Lancaster JW**. Curricular integration and evaluation of the Joint Commission of Pharmacy Practitioners (JCPP) pharmacist patient care process. Presented at: AACP Annual Meeting; July 2016; Anaheim, CA.
- **Andrew Miesner**: BCPS recertification.
- **Beth Resman-Targoff**: "Rheumatoid arthritis in the geriatric patient, secondary prevention, polypharmacy and challenges" and "Interprofessional case discussion." Invited talks at: Clinical Focus Course, Association of Rheumatology Health Professionals; November 12, 2016; Washington, DC.
- **Jon Wietholter**: July 2016: Facilitator's Workshop: Clinical Pharmacy in South Africa. Presented at: University of the Western Cape in Cape Town, South Africa.

Ambulatory Care PRN

Promotions

- **Mate M. Soric**: Vice Chair, Practice-Based Research.

Awards

- **Marissa Salvo**: 2016 University of Connecticut School of Pharmacy's Faculty Preceptor of the Year Award.
- **Mate M. Soric**: American College of Clinical Pharmacy New Clinical Practitioner Award.

Grants

- **Sarah L. Anderson**: University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences.
- **Ashley Crowl**: New Investigator Award, AACP (with mentors Sarah Shrader and Crystal Burkhardt): Best Practices for Assessment of Interprofessional Team-Ready Behaviors on APPEs.
- **Glenn Herrington**: Alliance for Patient Medication Safety Gaps in Diabetes Care Residency Incentive Grant.
- **Adriane N. Irwin**: Principal Investigator, 2017 AACP New Investigator Award: Exploring Patient Perceptions of Pain Contracts and the Role of the Pharmacist, \$9988.

Publications

- McEvoy DS, Sittig DF, Hickman TT, Aaron S, Ai A, **Amato M**, Bauer DW, Fraser GM, Harper J, Kennemer A, Krall MA, Lehmann CU, Malhotra S, Murphy DR, O'Kelley B, Samal L, Schreiber R, Singh H, Thomas EJ, Vartian CV, Westmorland J, McCoy AB, Wright A. Variation in high-priority drug-drug interaction alerts across institutions and electronic health records. *J Am Med Inform Assoc* 2017;24:331-8.
- **Amato MG**, Salazar A, Hickman TT, Quist AJL, Volk L, Wright A, McEvoy D, Slight SP, Bates DW, Schiff GD. Computerized prescriber order entry (CPOE) related patient safety reports: analysis of 2522 errors. *J Am Med Inform Assoc* 2017;24:316-22.
- Her QL, **Amato MG**, Seger DL, Gilmore JF, Fanikos J, Fiskio JM, Bates DW. Review of non-formulary medication (NFM) approvals in an academic medical center. *Jt Comm Jnl Qual Saf* 2017;43:89-96.
- Wong A, **Amato MG**, Seger DL, Slight SP, Beeler PE, Dykes PC, Fiskio JM, Orav EJ, Eguale T,

Silvers ER, Bates DW. Evaluation of medication-related clinical decision support alert overrides in the intensive care unit. *J Crit Care* 2017.

- **Anderson SL**, Kattappuram R, **Marrs JC**, Joseph NM. Intentional brodifacoum ingestion. *Am J Med* 2017;130:e27-8.
- **Castelli G**, Petrone A, Xiang J, Shrader C, King D. Rates of nonsteroidal anti-inflammatory drug use in patients with established cardiovascular disease: a retrospective, cross-sectional study from NHANES 2009-2010. *Am J Cardiovasc Drugs* 2017 Jan 6.
- Dooley P, Doolittle J, Knauss K, **Crowl A**. Atrial fibrillation: effective strategies using the latest tools. *J Fam Pract* 2017;66:16-25.
- **Dixon DL**, Carbone S, Abbate A. Letter by Dixon et al Regarding Article, "Watching Television and Risk of Mortality from Pulmonary Embolism Among Japanese Men and Women: The JACC Study (Japan Collaborative Cohort)." *Circulation* 2016;134:e499-e500.
- Carbone S, Canada J, Buckley L, Trankle C, **Dixon DL**, Buzzetti R, Arena R, Van Tassell B, Abbate A. Obesity contributes to exercise intolerance in heart failure with preserved ejection fraction. *J Am Coll Cardiol* 2016;68:2487-8.
- Bradley JN, **Edwards KL**, Gunter JT, Weideman RA, Kelly KC. Provider decisions and patient outcomes after premature metformin discontinuation. *Diabetes Spect* 2017;30:17-22.
- **Gavini M**, Faber ES, Birnbaum A, Sadovsky R. Who really manages our patients' medications? A study of inner city adults over 40 years of age. *J Am Pharm Assoc* (2003). 2016 Dec 10.
- Faber ES, **Gavini M**, Ramirez R, Sadovsky R. Rhabdomyolysis after coadministration of atorvastatin and sacubitril/valsartan (Entresto™) in a 63-year-old woman. *Drug Saf Case Rep* 2016;3:14.
- **Hill LG**. Coprescribing naloxone: a moral imperative? *iForumRx* website. <http://iforumrx.org/node/353>. Published 11/7/16.
- **Hill LG**, Bratberg JP, Haines ST. Opioid safety and overdose prevention podcast. *iForumRx* website. <http://apple.co/2esm8zd>. Published 10/21/16.
- Corbo JM, Delellis TM, **Hill LG**, Rindfuss SL. ACE inhibitors or ARBs to prevent CKD in patients with microalbuminuria. *Am Fam Physician* 2016;94:652-3.
- **Irwin AN**, Ham Y, Gerrity TM. Expanded roles for pharmacy technicians in the medication reconciliation process: a qualitative review. *Hosp Pharm* 2017;52:44-53.

- **Martin MT**. Gastrointestinal disorders. In: Bainbridge JL, Cardone K, Cross LB, et al., eds. *Updates in Therapeutics®: Ambulatory Care Pharmacy Preparatory Review and Recertification Course*, 2017 ed. Lenexa, KS: American College of Clinical Pharmacy, 2017:597-708.
- **Martin MT**, Faber DM. Patient satisfaction with the clinical pharmacist and prescribers during hepatitis C virus management. *J Clin Pharm Ther* 2016;41:645-9.
- **Martin MT**, Telebak E, Taylor P, Volozhina O. Development of a specialty medication prior authorization service at an urban academic medical center. *Am J Health Syst Pharm* 2016;73:1174-9.
- **Oung AB**, Saseen J. Do statins reduce the effectiveness of the influenza vaccine? *Evid Based Pract* 2017;20:9.
- Burke K, **Schumacher C**, Harpe S. SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature. *Pharmacotherapy* 2017;37:187-94.
- Ulbrich TR, Rogers J, **Soric MM**. Top 10 residency application mistakes. *Student Pharmacist* 2016;13:14-5.

Other Notable Achievements

- **Sarah L. Anderson**: Most accessed paper in *Pharmacotherapy* in 2016: "The effect of medical marijuana on migraine headache frequency in an adult population."
- **Eric Burke**: SE Alaska Chair, Alaska Pharmacists Association Board of Directors.
- **Dave L. Dixon**: BCACP certification.
- **Regina Ginzburg**: CDE and BC-ADM certification.
- **Lucas G. Hill**: Director, Operation Naloxone: Interprofessional opioid overdose prevention program for college campuses, health professionals, and community members.
- **Wendy Mobley-Bukstein**: Health and Wellness Coach (CHWC) certification.
- **Jordan Sedlacek**: BCACP certification.
- **Katie Traylor**: BCACP and BC-ADM certification.

Oral Presentations

- **Deming P, Martin MT, Rife K**. Hepatitis C virus: the newest strategies for management and treatment. CPE presented at: American College of Clinical Pharmacy 2016 Clinical Reasoning Series. Material also offered as a webinar. October 22, 2016; Hollywood, FL.

- **Martin MT.** Updates on gastrointestinal disorders. CPE presented at: American College of Clinical Pharmacy Updates in Therapeutics® 2017 Ambulatory Care Preparatory Review and Recertification Course; February 18, 2017; Jacksonville, FL.
- **Martin MT.** The future of HCV management for managed care: differentiating therapy by patient characteristics. CE presented for: PRIME at the Academy of Managed Care Pharmacy (AMCP) Ohio-Kentucky Chapter Meeting; September 20, 2016; West Chester, OH.
- **Martin MT.** Optimizing HCV treatment continuity and outcomes: empowering pharmacists to take action. CPE presented at: Pharmacy Learning Network Regional Meeting; March 4, 2017; Orange County, CA.

Cardiology PRN

Promotions

- **Jessica Bellone:** Associate Professor, Concordia University Wisconsin.
- **Brie Dunn:** Associate Dean, Outcomes Assessment & Accreditation, University of South Carolina College of Pharmacy.

Awards

- **Sally Arif:** Outstanding Faculty Advisor Award, Midwestern University Student Senate.
- **Jason Karnes:** University of Florida Outstanding Young Alumnus.

Grants

- **William L. Baker:** AHRQ Grant \$355,000: Pharmacologic Management of Asthma. Role, Coinvestigator.
- **Leo Buckley:** Pharmacometabolomic Response to Interleukin-1 Blockade in Patients with Recently Decompensated Heart Failure (Heart Failure Society of America to Leo Buckley [Principal Investigator]).
- **Jason Karnes:** American Heart Association Scientist Development Grant.

Publications

- **Arif SA, Tran T.** Deep venous thrombosis. In: Schwinghammer TL, Koehler JM, Borchert JS, et al., eds. *Pharmacotherapy Casebook: A Patient-Focused Approach*, 10th ed. New York: McGraw-Hill, 2017. In press.

- Bader F, **Atallah B**, Brennan LF, et al. Heart failure in the elderly: ten peculiar management considerations. *Heart Fail Rev* 2017.
- Sadik GZ, **Atallah B**, Stapleton J, Bader F. Appropriateness of evidence-based therapy in patients referred to a specialized heart failure clinic in a developing country. *J Card Fail* 2016;22:S36.
- **Baker WL.** Treating arrhythmias with adjunctive magnesium: identifying future research directions. *Eur Heart J Cardiovasc Pharmacother* 2016 Sep 15. [Epub ahead of print]
- **Baker WL**, Coleman CI. Vitamin C for prevention of post-cardiothoracic surgery atrial fibrillation: a meta-analysis. *Am J Health Syst Pharm* 2016;73:2056-66.
- Weeda ER, Nicoll BS, Coleman CI, Sharovetskaya A, **Baker WL.** Association between weekend admission and in-hospital mortality for variceal and nonvariceal upper gastrointestinal hemorrhage: an observational study and meta-analysis. *Int Emerg Med* 2016 Aug 17. [Epub ahead of print]
- Weymann A, Sabashnikov A, Ali-Hassan-Sayegh S, Popov AF, Mirhosseini SJ, **Baker WL**, Lotfaliani M, Liu T, Dehghan H, Yavuz S, de Oliveira Sa MPB, Jang J, Meng L, D'Ascenzo F, Deshmukh AJ, Biondi-Zoccai G, Dohmen PM, Calking H; for the Integrated Meta-analysis of Cardiac Surgery and Cardiology Group (IMCSC-Group). Predictive role of coagulation, fibrinolytic, and endothelial markers in patients with atrial fibrillation, stroke and thromboembolism: a meta-analysis, meta-regression and systematic review. *Med Sci Monit Basic Res.* In press.
- **Bress A, Cavallari LH, DiDomenico RJ.** Ischemic heart disease. In: Katz M, Matthias K, Chisholm-Burns MA, eds. *Pharmacotherapy Principles and Practice Study Guide: A Case-Based Care Plan Approach*, 4th ed. New York: McGraw-Hill, 2017:chap 5.
- Carbone S, Canada JM, **Buckley LF**, Trankle CR, **Dixon DL**, Buzzetti R, Arena R, **Van Tassell BW**, Abbate A. Obesity contributes to exercise intolerance in heart failure with preserved ejection fraction. *J Am Coll Cardiol* 2016;68:2487-8.
- Gryka R, **Buckley LF**, Anderson S. Vorapaxar: the current role and future directions of a novel protease-activated receptor antagonist for risk reduction in atherosclerotic disease. *Drugs R D* 2017. [Epub ahead of print]
- Trankle CR, Canada JM, **Buckley LF**, Carbone S, **Dixon DL**, Arena R, **Van Tassell BW**, Abbate A. Impaired myocardial relaxation with exercise

determines peak aerobic exercise capacity in heart failure with preserved ejection fraction. ESC Heart Fail 2017. In press.

- **Chow SL**, Hoeben B. Peripheral artery disease. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. *Pharmacotherapy: A Pathophysiologic Approach*, 10th ed. New York: McGraw-Hill, 2017.
- **Chow SL**, Maisel A, Anand I, Bozkurt B, De Boer R, Greenberg B, Felker M, Januzzi J, Kiernan M, Fonarow G, Liu P, Wang T, Yancy C, Zile M. AHA advisory statement: the role of biomarkers for the prevention, assessment, and management of heart failure. *Circulation* 2017. In press.
- Gandhi PU, **Chow SL**, Rector TS, Krum H, Gaggin HK, McMurray JJ, Zile MR, Komajda M, McKelvie RS, Carson PE, Januzzi JL Jr, Anand IS. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. *J Card Fail* 2017;23:20-8.
- ter Maaten JM, Rao VS, Hanberg JS, Wilson PF, Bellumkonda L, Assefa M, Broughton SJ, **D'Ambrosi J**, Tang WHW, Damman K, Voors AA, Ellison DH, Testani JM. Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure. *Eur J Heart Fail* 2017.
- Kim K, Lee TA, Touchette DR, **DiDomenico RJ**, Ardani AK, Walton SM. Contemporary trends in oral antiplatelet agent use in patients treated with percutaneous coronary intervention for acute coronary syndrome. *J Manag Care Spec Pharm* 2017;23:57-63.
- **Dixon DL**, Carbone S, Abbate A. Letter by Dixon et al Regarding Article, "Watching Television and Risk of Mortality from Pulmonary Embolism Among Japanese Men and Women: The JACC Study (Japan Collaborative Cohort)." *Circulation* 2016;134:e499-e500.
- **Dixon DL**, Trankle C, **Buckley L**, Parod E, Carbone S, **Van Tassell BW**, Abbate A. A review of PCSK9 inhibition and its effects beyond LDL receptors. *J Clin Lipidol* 2016;10:1073-80.
- **Dobesh PP**, Fanikos J. Reducing the risk of stroke in patients with nonvalvular atrial fibrillation with direct oral anticoagulants: is one of these not like the others? *JAFIB* 2016;9:66-74.
- **Dobesh PP**, Varnado S, Doyle M. Antiplatelet agents in cardiology: a report on aspirin, clopidogrel, prasugrel, and ticagrelor. *Curr Pharm Des* 2016;22:1918-32.
- Flaker GC, Theriot P, Binder LG, **Dobesh PP**, Cukler A, Doherty JU. Management of periprocedural anticoagulation: a survey of contemporary practice. *J Am Coll Cardiol* 2016;68:217-26.
- **Finks SW**, **Trujillo TC**, **Dobesh PP**. Management of venous thromboembolism: recent advances in oral anticoagulation therapy. *Ann Pharmacother* 2016;50:486-501.
- Shah V, Dileep A, Dickens C, **Groo V**, Welland B, Field J, Baumann M, Flores JD Jr, Shroff A, Zhao Z, Yao Y, Wilkie D, Boyd AD. Patient-centered tablet application for improving medication adherence after a drug eluting stent. *Front Public Health*. Accepted for publication.
- **Groo VL**, Goncharenko A. Overview of hyperlipidemia and hypertension. *Pharmacy tech topics™* by Illinois Council of Health-System Pharmacists 2016;21:1-43.
- **Hager K**, **Anastasia E**, **Parra D**. Uncontrolled hypertension. In: Katz M, Matthias K, Chisholm-Burns MA, eds. *Pharmacotherapy Principles and Practice Study Guide: A Case-Based Care Plan Approach*, 4th ed. Columbus, OH: McGraw-Hill, 2017:chap 3.
- **Hale GM**, Valdes J, **Brenner M**. A review of the treatment of primary orthostatic hypotension. *Ann Pharmacother* 2017. [Epub ahead of print]
- McCrink KA, Brill A, Jafferjee M, Valero TR, Marrero C, **Hale GM**, Lymperopoulos A, Rodriguez MM. β 1-Adrenoceptor Arg389Gly polymorphism confers differential β -arrestin binding tropism in cardiac myocytes. *Pharmacogenomics* 2016;17:1611-20.
- Chessman KH, **Haney J**. Disorders of sodium and water homeostasis. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. *Pharmacotherapy: A Pathophysiologic Approach*, 10th ed. New York: McGraw-Hill, 2017:49.1-49.
- Maxwell WD, Mohorn PL, **Haney JS**, Phillips CM, Lu ZK, Clark K, Corboy A, Ragucci KR. Impact of an advanced cardiac life support simulation laboratory experience on pharmacy student confidence and knowledge. *Am J Pharm Educ* 2016;80:Article 140.
- Thompson AN, McKinzie BP, **Haney JS**, **Nappi JM**, Pilch N. Pharmacy residency training measured through a standardized knowledge test. *Am J Health Syst Pharm* 2016;73:2095-8.
- **Harris JR**, **Hale GM**, **Schwier NC**. Pharmacotherapy of vasospastic angina. *J Cardiovasc Pharm Ther* 2016;21:439-51.
- **Jennings DL**. Heart failure therapy in 2016: SHIFTing the PARADIGM from antiquated

therapies toward novel agents. *Ann Pharmacother* 2016 Oct 3.

- **Jennings DL.** Letter by Jennings Regarding Article, "Stroke Risk and Mortality in Patients with Ventricular Assist Devices." *Stroke* 2017;48:e26.
- **Jennings DL, Baker WL.** Pre-cardiac transplant amiodarone use is not associated with post-operative mortality: an updated meta-analysis. *Int J Cardiol* 2017.
- Ton KV, Eisenberger A, **Jennings DL**, Colombo PC, Topkara VK. Relationship of hemolysis with discordance in paired activated partial thromboplastin time and anti-factor Xa measurements in continuous-flow left ventricular assist device patients. *J Heart Lung Transplant* 2016;35:1365-7.
- Topkara VK, Coromilas EJ, Garan AR, Li RC, Castagna F, **Jennings DL**, Yuzefpolskaya M, Takeda K, Takayama H, Sladen RN, Mancini DM, Naka Y, Radhakrishnan J, Colombo PC. Preoperative proteinuria and reduced glomerular filtration rate predicts renal replacement therapy in patients supported with continuous-flow left ventricular assist devices. *Circ Heart Fail* 2016;9(12).
- **Karnes JH**, Shaffer CM, Bastarache L, Gaudieri S, Glazer AM, Steiner H, Mosley JD, Mallal S, Denny JC, Phillips EJ, Roden DM. Comparison of allelic imputation programs. *PLoS One* 2017. In press.
- Aljabri A, Huckleberry Y, **Karnes JH**, Gharaibeh M, Kutbi S, Raz Y, Yun S, Abraham I, Erstad B. Cost-effectiveness of anticoagulants for the management of suspected heparin-induced thrombocytopenia in the United States. *Blood* 2016;128:3043-51.
- Mosley JD, Witte J, Larkin E, Bastarache L, Shaffer CM, **Karnes JH**, Stein CM, Phillips EJ, Hebring S, Brilliant M, Mayer J, Ye Z, Roden DM, Denny JC. Identifying genetically driven clinical phenotypes using linear mixed models. *Nat Commun* 2016;7:11433.
- **Khazan E, Anastasia E, Hough A, Parra D.** Pharmacist-managed ambulatory blood pressure monitoring service. *Am J Health Syst Pharm* 2017;74:190-5.
- Dunker A, **Kolanczyk DM**, Maendel C, Patel AR, Pettit NN. Impact of the FDA warning for azithromycin and risk for QT prolongation on utilization at an academic medical center. *Hosp Pharm* 2016;51:830-3.
- **McConnell KJ.** Cardiology update: 2016. *Pharmacy Today* 2016;22:70-84.
- **McConnell KJ.** Cardiology II. In: Burke J, Cauffield J, El-Ibiary S, et al., eds. *Updates in Therapeutics*®:

Pharmacotherapy Preparatory Review and Recertification Course, 2017 ed. Lenexa, KS: American College of Clinical Pharmacy, 2017:2-63–2-130.

- **McConnell KJ**, Guzman OE, Pherwani N, Spencer DD, Van Cura JD, Shea KM. Operational and clinical strategies to address drug cost-containment in the acute care setting. *Pharmacotherapy* 2017;37:25-35.
- Thompson AN, McKinzie BP, **Nappi JM, Haney JS**, Pilch N. Making the transition from student to resident: a method to individualize a PGY1 program. *Pharmacy* 2016;4:31.
- **Ng TM**, Menon R, Hauptman PJ. Reconfiguring the hospital-to-home transition into an active treatment period for patients with heart failure. *JAMA Cardiol* 2017.
- **Oliphant CS**, Owens RE, Bolorunduro OB, Jha SK. Ivabradine: a review of labeled and off-labeled uses. *Am J Cardiovasc Drugs* 2016;16:337-47.
- Alabdian NA, Gosmanova EO, Tran QT, **Oliphant CS**, Hu P, Broyles JE, Hudson JQ. Risk factors for acute kidney injury in patients continued on renin-angiotensin system blockers during hospitalization. *Am J Med Sci* 2017;353:172-7.
- Goswami R, **Oliphant CS**, Youssef H, Morsy M, Khouzam RN. Radial artery occlusion after cardiac catheterization: significance, risk factors and management. *Curr Probl Cardiol* 2016;41:214-27.
- Marler J, Mohrien K, Kimmons LA, Vandigo JE, **Oliphant CS**, Boucher AN, Jones GM. Effects of propofol on vasopressor use in patients with sepsis and severe sepsis: a pilot study. *J Crit Care* 2016;35:155-60.
- Slomka T, Lennon ES, Akbar H, Gosmanova EO, Bhattacharya SM, **Oliphant CS**, Khouzam RN. Effects of renin-angiotensin-aldosterone system blockade in patients with end-stage renal disease. *Am J Med Sci* 2016;351:309-16.
- Mitrugno A, Sylman JL, Ngo ATP, **Pan J**, Sears RC, **Williams CD**, McCarty OJT. Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: implications for the oncoprotein c-MYC. *Am J Physiol Cell Physiol* 2017;312:C176-80.
- **Saseen JJ, Ripley TL**, Bondi D, Burke JM, Cohen LJ, McBane S, **McConnell KJ**, Sackey B, Sanoski C, Simonyan A, Taylor J, Vande Griend JP. ACCP clinical pharmacist competencies. ACCP guideline. *Pharmacotherapy* 2017. In press.

- **Schwier NC, Hale G, Davies ML.** Treatment of adults with idiopathic recurrent pericarditis: novel use of immunotherapy. *Pharmacotherapy* 2017 [Epub ahead of print]
- **Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Flockhart DA, Kovacs RJ.** Influence of oral progesterone administration on drug-induced QT interval lengthening. A randomized, placebo-controlled crossover trial. *JACC Clin Electrophysiol* 2016;2:765-74.
- Abdelhady AM, Shugg T, Thong N, Lu JB, Kreutz Y, Jaynes HA, Robarge JD, **Tisdale JE**, Desta Z, Overholser BR. Efavirenz inhibits the human ether-a-go-go related current (hERG) and induces QT interval prolongation in *CYP2B6**6*6 allele carriers. *J Cardiovasc Electrophysiol* 2016;27:1206-13.
- Koehler JM, **Tisdale JE.** Hypertension. In: Schwinghammer TL, Koehler JM, Borchert JS, et al., eds. *Pharmacotherapy Casebook. A Patient-Focused Approach*, 10th ed. New York: McGraw-Hill, 2017:53-6.
- Melton BL, Zillich AJ, Saleem J, Russ AL, **Tisdale JE**, Overholser BR. Iterative development and evaluation of a pharmacogenomic-guided clinical decision support system for warfarin dosing. *Appl Clin Inform* 2016;7:1088-106.
- Trujillo JM, McNair CD, Linnebur SA, Valdez C, **Trujillo TC.** The impact of a stand-alone communications course series integrated with pharmacotherapy courses and IPPEs. *Am J Pharm Educ* 2016;80:Article 174.
- **Wiggins BS**, Sanoski C. Advanced cardiac life support and post-cardiac arrest management. In: *Cardiology Critical Care. Critical Care Self-Assessment Program (CCSAP)*. American College of Cardiology, 1st ed. January 2017.
- **Wiggins BS, Saseen JJ, Page RL, Reed BN**, Sneed K, Kostis JB, Lanfear D, Virani S, Morris PB. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease. A scientific statement from the American Heart Association. *Circulation* October 2016. <http://circ.ahajournals.org/content/early/2016/10/17/CIR.0000000000000456>.
- Floroff CK, Palm NM, Steinberg DH, Powers ER, **Wiggins BS.** Use of higher maximum doses and infusion rates compared with those used in standard unfractionated heparin therapy is associated with adequate anticoagulation without increased bleeding in both obese and nonobese patients with cardiovascular indications. *Pharmacotherapy* 2017.

Presentations

- DePatis K, McLaughlin M, Kliethermes MA, Quinones-Boex A, **Kolanczyk D**, Schmidt J, Tran T, Vest KM. Factors influencing fourth year pharmacy student pursuit of research. Student poster presented at: ASHP Midyear Meeting; December 2016; Las Vegas, NV.
- Masic D, Greenhalgh E, **Kolanczyk DM.** Evaluation of appropriate prescribing of rivaroxaban and apixaban and clinical outcomes in a large academic medical center. Student poster presented at: ASHP Midyear Meeting; December 2016; Las Vegas, NV.

New ACCP Fellows

- **Amber Beitelshes**
- **Dave Dixon**
- **Sherry LaForest**
- **Harminder Sikand**
- **Kyle Weant**

Other Notable Achievements

- **William L. Baker:** Fellow, American Heart Association.
- **Dave L. Dixon:** BCACP certification.
- **Jason Haney:** BCCCP certification.

James E. Tisdale:

- Board of Directors, AZCERT.
- Electrophysiology Section Leadership Council, American College of Cardiology.

Brian J. Trevarrow: Presented at: Seventh Annual Seminar on Therapeutics and Clinical Practice of Pharmaceutical Care:

- "Competence and Performance Assessment for Clinical Pharmacists."
- "Methods on Becoming an Outstanding and Qualified Clinical Pharmacist."
- "Anticoagulation and Antithrombotic Therapy Management in Hospitalized Patients."
- Pharmacist educational symposium offered at Tongji University School of Medicine in conjunction with Department of Pharmacy, Shanghai Yangpu District Central Hospital, Yu Zicheng, M.Sc., Ph.D., Director; August 2016; Shanghai, PR China.

Toby C. Trujillo:

- CVT Member, Cardiovascular Team Section Leadership Council, American College of Cardiology.

- Chair, Research and Scholarship Committee, Cardiology PRN, American College of Clinical Pharmacy.
- Member, Legislative Committee, Colorado Pharmacists Society.

Central Nervous System PRN

Promotions

- **Joshua Caballero:** Chair, Department of Clinical and Administrative Sciences, Larkin Health Sciences Institute, Miami, Florida.

Awards

- **Stephanie Nichols:** Cardinal Health Generation Rx Champion Award (for excellence in community-based prescription drug abuse prevention).

Grants

- **Joshua Caballero:** Health Literacy Assessment and Intervention to Reduce Disparities: FLIGHT/VIDAS II. Supplement PA16-288:3R01MD010368-01S1. 2016. \$51,950. Co-Principal Investigator (awarded).

Publications

- **Anderson PD.** Drug-induced aggression and violence. O'Donnell's Drug Injury, 4th ed. Tucson: Lawyers & Judges Publishing, 2016.
- **Chen JJ.** Quetiapine in the treatment of Huntington's chorea: a case series. *Ca Pharm* 2016;63:11-4.
- **Chen JJ.** Zonisamide for the management of essential tremor: an illustrative case report on long-term effectiveness. *Ca Pharm* 2017;64:11-4.
- **Chen JJ.** Parkinson's disease psychosis: a pharmacist's update of new treatment options. *Pharmacy Times* 2016;82:81-92.
- **Gören JL, Rose AR, Engle RL, Smith EG, Christopher M, Rickles NM, Semla T, McCullough MB.** Organizational characteristics of high- and low clozapine utilization. *Psychiatr Serv* 2016;67:1189-96.
- **Gören JL, Rose AJ, Smith EG, Ney JP.** The business case for expanded clozapine utilization. *Psychiatr Serv* 2016;67:1197-205.
- **Nichols SD, Bulman M, Tisher A, Campbell J.** A case of possible iatrogenic ketamine-induced mania in a patient being treated for post-operative pain. *Psychosomatics* 2016;57:543-6.

- **Kasteleijn Nolst-Trenité DG, Genton P, Brandt C, Reed RC.** The 'Photosensitivity Model' is (also) a model for partial (focal) seizures. *Epilepsy Res* 2016 Dec 2.
- **Ramey P, Osborn MR, Lowen KM, Reed RC, Abou-Khalil B.** Unexplained spikes in lamotrigine serum concentration: nonlinear elimination? *Acta Neurol Scand* 2017;135:240-6.
- **Sitges M, Aldana B, Reed RC.** Effect of the anti-depressant sertraline, the novel anti-seizure drug vinpocetine and several conventional antiepileptic drugs on the epileptiform EEG activity induced by 4-aminopyridine. *Neurochem Res* 2016;41:1365-74.
- **Sitges M, Chiu LM, Reed RC.** Effects of levetiracetam, carbamazepine, phenytoin, valproate, lamotrigine, oxcarbazepine, topiramate, vinpocetine and sertraline on presynaptic hippocampal Na⁺ and Ca²⁺ channels permeability. *Neurochem Res* 2016;41:758-69.

New ACCP Fellows

- **Ronald Reed**

Other Member Accomplishments

- **Stephanie Nichols:** Adjunct Clinical Assistant Professor of Psychiatry, Tufts University, School of Medicine.
- **Ronald Reed:** Fellow, American Epilepsy Society (FAES), as of December 2017.
- **Tim Welty:** Chair-Elect, Council on Clinical Activities, American Epilepsy Society.

Clinical Administration PRN

Promotions

- **Eric Harvey:** Director, System-wide Clinical Pharmacy, Swedish Medical System, Seattle, Washington.
- **Andrew Lucas:** Research Assistant Professor, UNC Eshelman School of Pharmacy.

Awards

- **Angela Black Smith:** NC Governor's Award for Excellence.

Critical Care PRN

The Critical Care PRN Recognition Committee has been completing its charges for the year. Several members have been nominated for ACCP offices and awards. The Critical Care PRN honors its members by presenting its own awards every year. Nominations are currently

open for these awards and will close in August 2017. PRN members were recognized for their achievements at the PRN business meeting at the 2016 ACCP Annual Meeting. If you are interested in joining the Recognition Committee, please e-mail Nick Peters (npeters.butler@gmail.com).

Promotions

- **John Allen:** Division Director, Infectious Diseases Pharmacy, HCA West Florida.
- **Kisha Grant:** Pharmacy Clinical Coordinator, Slidell Memorial Hospital.
- **Kimberly Levasseur-Franklin:** Senior Clinical Pharmacy Specialist, Critical Care, Tufts Medical Center.
- **Hesham Mourad:** Assistant Professor of Pharmacy, Mayo Clinic College of Medicine.
- **Nick Peters:** Residency Coordinator, Suburban Hospital, Johns Hopkins Medicine.

Awards

- **Sarah Blackwell:** New Practitioner of the Year, Alabama Society of Health-System Pharmacists.
- **Scott Bolesta:** Presidential Citation, SCCM.
- **Mitchell Buckley:** ASHP Foundation Pharmacy Practice Research Literature Award.
- **Sonia Everhart:** Best Practices Award, ASHP.

Leslie Hamilton:

- AACP Walmart Scholar.
- University of Tennessee Most Influential Professor.

Drayton Hammond:

- Arkansas chapter of American College of Clinical Pharmacy New Clinical Practitioner Award.
- American College of Clinical Pharmacy Critical Care PRN Leadership Award.
- Arkansas Association of Health-System Pharmacists New Practitioner of the Year.

Desiree Kosmisky:

- ASHP Best Practices Award.
- SCCM Clinical Pharmacy and Pharmacology Section Young Pharmacist Investigator Award.
- **Eric Mueller:** University of Cincinnati James L. Winkle College of Pharmacy Distinguished Alumni Award.
- **Joseph Muench:** Pharmacy Times 2016 Technology Innovator of the Year Finalist.

Grants

- **Bolesta S:** Advancing the Cardiovascular Science of Vitamin C in Cardiac Surgery Patients. Submitted August 2016; Wilkes University. Amount requested: \$10,000 in direct costs. Funding period: 01/01/2017-12/31/2017. Receiving agency/agent: Wilkes University.

Publications

- DeGrado JR, Hohlfelder B, Ritchie BM, **Anger KE**, Reardon DP, Weinhouse GL. Evaluation of sedatives, analgesics, and neuromuscular blocking agents in adults receiving extracorporeal membrane oxygenation. *J Crit Care* 2017;37:1-6.
- Dube KM, Szumita PM, Rocchio MA, Lee PS, **Anger KE**. The effect of concomitant sirolimus and propofol therapy on triglyceride concentrations in critically ill patients. *Am J Ther* 2016 Jun 23. [Epub ahead of print]
- Hohlfelder BA, **Anger KE**, Szumita PM, Degrado JR. Etanercept for the treatment of transplantation-related lung injury after hematopoietic stem cell transplantation. *Am J Ther* 2016. In press.
- Torbic H, Szumita PM, **Anger KE**, Nuccio P, LaGambina S, Weinhouse G. Clinical and economic impact of formulary conversion from inhaled Flolan to inhaled Veletri for refractory hypoxemia in critically ill patients. *Ann Pharmacother* 2016;50:106-12.
- **Beckman EJ**. Extracorporeal therapies in children. In: Buck ML, Manasco KB, eds. *Pediatric Self-Assessment Program, 2016 Book 2. Pediatric Critical Care*. Lenexa, KS: American College of Clinical Pharmacy, 2016:55-79.
- Rivosecchi RM, Kellum JA, Dasta JF, Armahizer MJ, **Bolesta S**, et al. Drug class combination-associated acute kidney injury. *Ann Pharmacother* 2016;50:953-72.
- **Buckley MS**, Muir J. Prophylaxis of stress ulcer and deep venous thrombosis. In: *Pain and Sedation/Support and Prevention Critical Care Self-Assessment Program*. Lenexa, KS: American College of Clinical Pharmacy, 2016.
- **Flannery AH**, Adkins DA, Cook AM. Unpeeling the evidence for the banana bag: evidence-based recommendations for the management of alcohol-associated vitamin and electrolyte deficiencies in the intensive care unit. *Crit Care Med* 2016;44:1545-52.
- **Flannery AH**, Oyler DR, Weinhouse GL. The impact of interventions to improve sleep on delirium

in the ICU: a systematic review and research framework. *Crit Care Med* 2016;44:2231-40.

- **Flannery AH**, Pandya K, Laine ME, Almeter PJ, Flynn JD. Managing the rising costs and high drug expenditures in critical care pharmacy practice. *Pharmacotherapy* 2017;37:54-64.
- Thompson Bastin ML, Neville NR, Parsons RE, **Flannery AH**, Tennant SJ, Johnson CA. An unusual case of *Salmonella Enteritidis* causing pneumonia, septic shock and multiple organ failure in an immunocompetent patient. *IDCases* 2016;6:85-9.
- **Hamilton LA**, Collins-Yoder A, Collins RE. DILI: drug induced liver injury. *AACN Adv Crit Care* 2016;27:430-40.
- **Hamilton LA**, Franks A, Heidel RE, McDonough SLK, Suda KJ. Assessing the utility of online learning and social media in pharmacy education. *Am J Pharm Educ* 2016;80:Article 97.
- Madere TC, Mendez JB, Nordmeyer ST, Heidel RE, **Hamilton LA**. Evaluation of intravenous acetaminophen on length of stay in abdominal surgery patients. *Hosp Pharm* 2016;51:230-6.
- Rowe AS, Mahbubani PS, Bucklin MH, Clark CT, **Hamilton LA**. Activated prothrombin complex concentrate versus plasma for reversal of warfarin-associated hemorrhage. *Pharmacotherapy* 2016;36:1132-7.
- **Hammond DA**, Hughes CA, Painter JT, Pennick RE, Chatterjee K, Boye B, Meena N. Impact of targeted educational interventions on *Clostridium difficile* infection treatment in critically ill adults. *Hosp Pharm* 2016;51:901-6.
- **Hammond DA**, Smith MN, Lee KC, Honein D, Quidley AM. Acute decompensated heart failure. *J Intensive Care Med* 2016 Sep 16. [Epub ahead of print]
- **Hammond DA**, Smith MN, Li C, Hayes SM, Lusardi K, Bookstaver PB. Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. *Clin Infect Dis* 2016 Dec 10. [Epub ahead of print]
- **Hammond DA**, Vines CE, McPhee AL, Bhandari NR, Jones KM, Meena N, Painter JT. Effect of etomidate on pneumonia development in critically ill, nontrauma patients. *J Intensive Care Med* 2016 Jan 1. [Epub ahead of print]
- Schwinghammer TL, Crannage AJ, Boyce EG, Bradley B, Christensen A, Dunnenberger HM, Fravel M, Gurgle H, **Hammond DA**, Kwon J, Slain D, Wargo KA. The 2016 ACCP Pharmacotherapy Didactic Curriculum Toolkit. *Pharmacotherapy* 2016;36:e189-94.
- Chessman KH, **Haney J**. Disorders of sodium and water homeostasis. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. *Pharmacotherapy: A Pathophysiologic Approach*, 10th ed. New York: McGraw-Hill, 2017:49.1-49.
- Maxwell WD, Mohorn PL, **Haney JS**, Phillips CM, Lu ZK, Clark K, Corboy A, Ragucci KR. Impact of an advanced cardiac life support simulation laboratory experience on pharmacy student confidence and knowledge. *Am J Pharm Educ* 2016;80:Article 140.
- Thompson AN, McKinzie BP, **Haney JS**, Nappi JM, Pilch N. Pharmacy residency training measured through a standardized knowledge test. *Am J Health Syst Pharm* 2016;73:2095-8.
- Thompson AN, McKinzie BP, Nappi JM, **Haney JS**, Pilch N. Making the transition from student to resident: a method to individualize a PGY1 program. *Pharmacy* 2016;4:31.
- **Jacobi J**. Liberal glucose targets for critically ill diabetic patients: is it time for large clinical trials with more personalized endpoints? *Ann Translational Med* 2016. <http://dx.doi.org/10.21037/atm.2016.08.64>.
- **Jacobi J**. Clinical pharmacists: practitioners who are essential members of your clinical care team. *Rev Med Clin Condes* 2016;27:571-7.
- Murray MJ, DeBlock H, Erstad B, Gray A, **Jacobi J**, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. *Crit Care Med* 2016;44:2079-103.
- Capino AC, Miller JL, **Johnson PN**. Clonidine for sedation and analgesia and withdrawal in critically ill infants and children. *Pharmacotherapy* 2016;12:1290-9.
- Duncan-Azadi CR, **Johnson PN**, Gormley AK. Midazolam withdrawal induced catatonia in a nine-year-old patient. *A Case Rep* 2017 Feb 8.
- Hughes KM, **Johnson PN**, Anderson MP, Sekar KC, Welliver RC, Miller JL. Comparison of amikacin pharmacokinetics in neonates pre and post a dosing protocol change. *J Pediatr Pharmacol Ther* 2017;22:33-40.
- Ibach BW, **Johnson PN**, Ernst KD, Harrison D, Miller JL. Initial dosing and taper complexity of methadone and morphine for treatment of neonatal abstinence syndrome. *J Pharm Technol* 2016;32:216-22.

- Ibach BW, Miller JL, Woo S, Harrison D, Standifer K, Hagemann TM, **Johnson PN**. Characterization of tolerance in children during fentanyl continuous infusions. *J Pediatr Intensive Care* 2016;1-8.
- Van Tuyl JS, Jones AN, **Johnson PN**. Meropenem-induced neutropenia in a neonate. *J Pediatr Pharmacol Ther* 2016;21:353-7.
- Elsoueidi R, Gresham C, Michael L, Chaney D, **Mourad H**. Chemotherapy dosing in achondroplastic dwarfism: a case report and review of literature. *J Clin Pharm Ther* 2016;41:733-5.
- **Mueller EW**. Infectious diseases I. In: Abel EE, Bauer SR, Benken ST, et al. Updates in Therapeutics®: Critical Care Pharmacy Preparatory Review Course, 2017 ed. Lenexa, KS: American College of Clinical Pharmacy, vol. 3. In press.
- **Mueller EW**. Infectious diseases I. In: Abel EE, Bauer SR, Benken ST, et al., eds. Updates in Therapeutics®: Critical Care Pharmacy Preparatory Review Course, 2016 ed. Lenexa, KS: American College of Clinical Pharmacy, 2016:267-307.
- Bauer SR, Abraham PE, Barletta JF, Brophy GM, Gonzales JP, Haas CE, MacLaren R, **Mueller EW**, Olsen KM, Lat I. Development and growth of the critical care pharmacotherapy trials network. *Am J Health System Pharm* 2017;74:287-93.
- Droege CA, **Mueller EW**. Fentanyl pharmacokinetics in critically ill patients: a demonstration of mixed effects. *Crit Care Med* 2016;44:240-2.
- Droege ME, Van Fleet S, **Mueller EW**. Practical application of antibiotic pharmacodynamics and dosing principles in patients with sepsis. *Crit Care Nurse* 2016;36:22-32.
- Isemann B, **Mueller EW**, Narendran V, Akinbi H. Impact of early sodium supplementation on weight gain in premature infants: a randomized, blinded placebo-controlled trial. *JPEN* 2016;40:342-9.
- **Muench J**. A Pharmacist's Guide to Inpatient Medical Emergencies, 1st ed. CreateSpace Independent Publishing Platform, 2016.
- Khanna A, **Peters NA**, Kim D. A multidisciplinary approach to PICS. *Critical Connections* 2017;1:10.
- Bennett S, Greenhalgh E, **Rech MA**. Off-label use of four-factor prothrombin complex concentrate: drug-induced coagulopathies, disease-induced coagulopathies, and attenuated dosing. In: Firstenberg MS, ed. Prothrombin Complex Concentrates: Advances in Research and Clinical Applications. Nova Science, 2017:chap 4.
- Kattub H, Sterk E, **Rech MA**, Bukar B, Khan S. Early recognition and treatment of sepsis after the

addition of lactate to critical laboratory call list. *J Intensive Care Med* 2016 Sep 11. [Epub ahead of print]

- Wong A, Erdman M, Hammond D, Holt T, Holzhausen J, Horng M, Huang LL, Jarvis J, Kram B, Kram S, Lesch C, Mercer J, **Rech MA**, Rivosecchi R, Stump B, Teevan C, Da S. Major publications in the critical care pharmacotherapy literature: January 2015 – December 2015. *Am J Health Syst Pharm* 2017 Jan 25. [Epub ahead of print]

New ACCP Fellows

- **John Allen**: American College of Critical Care Medicine.
- **Pete Johnson**: Pediatric Pharmacy Advocacy Group.

Other Notable Achievements

Karen Berger:

- Board Certified Critical Care Pharmacist (BCCCP)
New York City Chapter of Health-System Pharmacists
President-Elect

- **Kara Birrer**: Chair-Elect of Perioperative Care PRN
- **Mitchell Buckley**: Board Certified Critical Care Pharmacist (BCCCP)

Elizabeth Beckman:

- BCCCP certification.
- Vice Chair, Advanced Knowledge Assessment in Pediatric Critical Care Committee (AKAPCC), SCCM.

Sarah Blackwell: BCCCP certification.

Scott Bolesta: Secretary-Treasurer, SCCM Research Section.

Mitchell Buckley:

- 2017 American College of Clinical Pharmacy Annual Meeting Planning Committee.
- Blame the benzos for ICU delirium! Culprit or innocent bystander? Platform presentation at: ASHP Midyear Meeting; December 2016; Las Vegas, NV.

Alexander Flannery:

- PGY2 Critical Care Residency Program Director at UK HealthCare.
- Vice Chair, American College of Clinical Pharmacy 2018 Annual Meeting Program Committee.
- American College of Clinical Pharmacy Research and Scholarship Academy Certificate.

Kisha Grant:

- BCPS certification.
- Secretary, Louisiana Society of Health-System Pharmacists.

Leslie Hamilton: Committee Co-chair, AACP Pharmacy Practice Section Awards.

Drayton Hammond:

- Chair-Elect, American College of Clinical Pharmacy Critical Care PRN.
- President, Arkansas chapter of American College of Clinical Pharmacy.
- Vice Chair, Professional Development Committee, American College of Clinical Pharmacy Education and Training PRN.
- Programming Site Co-coordinator, SE chapter of SCCM.
- Charge Leader, Mentor-Mentee Program for the Membership Committee for CPP, SCCM.
- Charge Leader, Journal Club Presentations for the Education Committee for CPP, SCCM.
- AACP Walmart Scholars Program Mentor for PGY1 Resident.

Jason Haney: BCCCP certification.

Desiree Kosmisky:

- Impact of television-ICU services across a health-care system. Poster presented at: Annual Meeting; October 2016; Hollywood, FL.
- ePharmacy services: how they can make a difference. Presented at: Philips Connect2Care Conference; October 2016; Orlando, FL.
- Tele-ICU pharmacist impact on glycemic control across a large healthcare system. Poster for best practices presented at: ASHP Midyear Meeting; December 2016; Las Vegas, NV.
- Characterization of telepharmacist interventions in hyponatremia management. Abstract accepted for presentation as a Research Snapshot at: SCCM Annual Congress; Honolulu, Hawaii (research snapshot presented by Sonia Everhart).

Kimberly Levasseur-Franklin: BCCCP certification.

Angel Maldonado: BCCCP certification.

Eric Mueller: Chair, Operations Committee, Critical Care Pharmacotherapy Trials Network.

Joseph Muench:

- Creator, online Critical Care Pharmacy Academy.
- Host, critical care pharmacy podcast, "The Elective Rotation."

- Manager, the Slack group, which surpassed 600 members in December 2016.

Katie Nault: BCCCP certification.

Megan Rech:

- BCCCP certification.
- Chair-Elect, SCCM CPP Research Committee.

Susan Smith: BCPS certification.

Ann Spry: Director-at-Large, Kansas Council of Health-System Pharmacy.

Trevor Warner:

- BCCCP certification.
- President, Northern Michigan Society of Health-System Pharmacists.

Cory Weaver: BCCCP certification.

Natalie Winings: BCCCP certification.

Drug Information PRN

Promotions

- **J. Russell May:** Associate Department Head, University of Georgia College of Pharmacy, Augusta.

Publications

- Britt RB, **Brown JN.** Characterizing the severe reactions of parenteral vitamin K1. Clin Appl Thromb Hemost 2016 Oct 22. [Epub ahead of print]
- Britt RB, Hashem M, Bryan WE, Kothapalli R, **Brown JN.** Economic outcomes associated with a pharmacist-adjudicated formulary consult service in a Veterans Affairs medical center. J Manag Care Spec Pharm 2016;22:1051-6.
- Griffin E, **Brown JN.** Pregabalin for the treatment of restless legs syndrome. Ann Pharmacother 2016;50:587-91.
- Loy BM, Britt RB, **Brown JN.** Memantine for the treatment of phantom limb pain: a systematic review. J Pain Palliat Care Pharmacother 2016;30:276-83.
- Yang S, Britt RB, Hashem M, **Brown JN.** Outcomes of pharmacy-led hepatitis C direct-acting antiviral (DAA) utilization management at a Veterans Affairs medical center. J Manag Care Spec Pharm 2016;23:364-9.
- **May DW,** Carroll M, May JR. Upper gastrointestinal ulceration. In: Tisdale JE, Miller DA, eds. Drug-Induced Diseases: Prevention, Detection, and Management, 3rd ed. Bethesda, MD: American

Society of Health-System Pharmacists, 2016. In preparation.

- **May DW**, Chisholm-Burns MA. Gastroesophageal reflux disease. In: Chisholm-Burns MA, Schwinghammer TL, Wells BG, et al., eds. *Pharmacotherapy Principles & Practice*, 4th ed. New York: McGraw-Hill, 2016:285-94.
- **May DW**, Thiman M, Rao S. Gastroesophageal reflux disease. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. *Pharmacotherapy A Pathophysiological Approach*, 10th ed. New York: McGraw-Hill, 2017:435-52.
- Bourg CA, **May DW**. Peptic ulcer disease. In: Chisholm-Burns MA, Schwinghammer TL, Wells BG, et al., eds. *Pharmacotherapy Principles & Practice*, 4th ed. New York: McGraw-Hill, 2016:295-306.
- Dennis VC, **May DW**, Kanmaz TJ, Reidt SL, Serres ML, Edwards HD. A review of pharmacy student learning during advanced pharmacy practice experiences in relation to the CAPE 2013 outcomes. *Am J Pharm Educ* 2016;80:Article 127.
- May JR, **May DW**. In: Malone PM, Malone MJ, eds. *Introduction to the concept of drug information*. In: *Drug Information—A Guide for Pharmacists*, 6th ed. New York: McGraw-Hill, 2016. In preparation.
- Phillips HJ, Lepkowsky-Harvey M, Holler J, **May DW**, May JR. Preceptor in training development—a commentary on current practice. *Am J Health Syst Pharm* 2016. Accepted for publication.
- Welston K, **May DW**. Gastrointestinal drugs. In: Ray SD, ed. *Side Effects of Drugs Annual*, vol 38. Amsterdam: Elsevier, 2016:379-93.
- Dorval E, **Thornby K**, Ottman A, Hubbard M. Useful resources for faculty and students serving on a curriculum committee in schools and colleges of pharmacy. *Curr Pharm Teach Learn* 2017;9:145-54.
- **Ward KE**. Pregnancy and lactation: therapeutic considerations. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. *Pharmacotherapy: A Pathophysiologic Approach*, 10th ed. New York: McGraw-Hill, 1229-46.

Presentations

- **Brown JN**. Implementation and outcomes of a post-graduate pharmacy residency learning experience in medical writing. Poster presented at: ASHP National Residency Preceptors Conference; 2016; Washington, DC.
- Johnson A, **Thornby K**. #Evidence-based? Exploring challenges with the quality, reporting, and

transparency of evidence in healthcare research. Presented at: ASHP Midyear Meeting; December 2016; Las Vegas, NV.

Education and Training PRN

The EDTR PRN was founded in 2002 after 22 ACCP members identified a need for educators to network with others having similar interests and to facilitate collaborative work to advance pharmacy education and training. The EDTR PRN now has over 600 members, and its mission statement still emphasizes the same values the PRN was created under. The mission statement for the EDTR PRN is “to promote dialogue and interaction among members and to develop programs that enhance the knowledge and skills of members involved in education and training within clinical pharmacy.”

The EDTR PRN again hosted mock interviews for students and residents attending the 2016 ACCP Annual Meeting in Hollywood, Florida. Over 50 students and residents took part in this opportunity to learn key interviewing skills from clinical faculty and practitioners in preparation for residency or initial career position interviews. Most participants were able to complete at least two rounds of mock interviews, receiving valuable feedback from several interviewers. We look forward to offering this activity at the 2017 Annual Meeting and ask that you encourage the students and residents who attend to take advantage of this opportunity. We also held an auction at the Annual Meeting to raise funds for the PRN. Fifteen items were donated by PRN members, and we raised \$267.

The Student and Postgraduate Trainee Support Committee worked with the PRN membership to continue offering three travel awards (two student awards and one postgraduate trainee award) for the Annual Meeting last year, which will be continued for the 2017 Annual Meeting. Watch the EDTR e-mail list for additional information as well as the Student and Resident sections of the ACCP website. In addition, together with the Professional Development Committee, the EDTR conducted poster walk-rounds at the Annual Meeting for PRN members presenting their scholarly work.

Promotions

Joshua Caballero: Chair, Department of Clinical and Administrative Sciences, Larkin Health Sciences Institute, Miami, Florida.

Cher Enderby:

- Program Director, PGY1 Pharmacy Residency, Mayo Clinic, Florida.
- Coordinator, Education and Staff Development, Mayo Clinic, Florida.

Mate M. Soric: Vice Chair, Practice-Based Research, Northeast Ohio Medical University.

Awards

- **Ashley Crowl:** New Investigator Award AACP (with mentors Sarah Shrader and Crystal Burkhardt): Best Practices for Assessment of Interprofessional Team-Ready Behaviors on APPEs.
- **Alex Isaacs:** Indiana Distinguished Young Pharmacist Award 2016 (Indiana Pharmacists Alliance).
- **Lindsay Saum:** Distinguished Alumni for Alpha Phi Chapter of Phi Delta Chi.
- **Mate M. Soric:** American College of Clinical Pharmacy New Clinical Practitioner Award.

Grants

- **Joshua Caballero:** Health Literacy Assessment and Intervention to Reduce Disparities: FLIGHT/VIDAS II. Supplement PA16-288:3R01MD010368-01S1. 2016. \$51,950. Co-Principal Investigator (awarded).
- **Emily Christenberry:** Increasing Uptake of Tdap and Herpes Zoster Vaccination in an Academic Family Medicine Clinic Along the United States-Mexico Border. Principal Investigator. University of Texas at El Paso University Research Institute Grant. Funded, \$5000.00. October 2016 – August 2017.

Publications

- **Andrus MR,** Stevenson TS, Eiland LS. Use of clinical intervention databases by student pharmacists and recent pharmacy graduates [letter]. *Am J Health Syst Pharm* 2016;73:1916.
- Phillippe HM, Wright BW, Bowerman KE, **Andrus MR.** Pharmacist interventions regarding the appropriateness of apixaban, rivaroxaban, dabigatran and warfarin in a university affiliated outpatient clinic. *J Pharm Technol* 2016;32:245-52.
- Dooley P, Doolittle J, Knauss K, **Crowl A.** Atrial fibrillation: effective strategies using the latest tools. *J Fam Pract* 2017;66:16-25.
- **Dy-Boarman E,** Martin D, Nisly SA. Use of a health screening and education event to change student attitudes towards the elderly. *Curr Pharm Teach Learn* 2017;9:101-7.
- Haines SL, **Dy-Boarman EA,** **Clifford KM,** Summa MA, Wilson, MN, Boyle JA, Peeters MJ. Methods used by US colleges/schools of pharmacy to

prepare student Pharmacists for careers in academia. *Am J Pharm Educ* 2017;81:Article 6.

- **Hill LG.** Coprescribing naloxone: a moral imperative? iForumRx website. <http://iforumrx.org/node/353>. Published 11/7/16.
- **Hill LG,** Bratberg JP, Haines ST. Opioid safety and overdose prevention podcast. iForumRx website. <http://apple.co/2esm8zd>. Published 10/21/16.
- Corbo JM, Delellis TM, **Hill LG,** Rindfuss SL. ACE inhibitors or ARBs to prevent CKD in patients with microalbuminuria. *Am Fam Physician* 2016;94:652-3.
- **Howard MH,** **Isaacs AN,** **Nisly SA.** Continuous infusion non-steroidal anti-inflammatory drugs for perioperative pain management. *J Pharm Pract.* [Epub ahead of print]
- Ulbrich TR, Rogers J, **Soric MM.** Top 10 residency application mistakes. *Student Pharmacist* 2016;13:14-5.
- Dunker A, **Kolanczyk DM,** Maendel C, Patel AR, Pettit NN. Impact of the FDA warning for azithromycin and risk for QT prolongation on utilization at an academic medical center. *Hosp Pharm* 2016;51:830-3.
- **Nisly SA,** **Isaacs AN,** White C, Chamberlin SM. 24-month pharmacotherapy residency: the what and how behind these programs. *Curr Pharm Teach Learn* 2016;8:796-803.
- **Nisly SA,** **Janzen KM,** **Steuber TD,** Trujillo TN. Alumni survey as a quality improvement tool for defining residency success [letter]. *Am J Health Syst Pharm* 2016;73:1722-5.
- **Peeters MJ,** Chen Y, Sexton M. Validation of the SPICE-R instrument among a diverse interprofessional cohort: a cautionary tale. *Curr Pharm Teach Learn* 2016;8:517-23.
- **Peeters MJ,** Harpe SE. Numbers etiquette in reports of pharmacy education scholarship. *Curr Pharm Teach Learn* 2016;8:896-904.
- **Peeters MJ,** Vaidya VA. A mixed-methods analysis in assessing students professional development by using an assessment for learning approach. *Am J Pharm Educ* 2016;80:Article 77.
- Baki G, Borden MJ, **Peeters MJ.** Introducing an undergraduate degree of cosmetic science and formulation design within a college of pharmacy. *Inov Pharm* 2017;8:Article 9.
- Ng GQ, **Sklar GE,** Chng HT. An evaluation of the completeness of drug-drug interaction-related information in package inserts. *Eur J Clin Pharmacol.*

- Tan CJY, **Sklar GE**. Characterisation and outcomes of adult patients with paracetamol overdose presenting to a tertiary hospital in Singapore. *Singapore Med J* 2016;1-25.
- **Soric MM**, Moorman JM, Boyle JA, Dengler-Criss CM. Prevalence and predictors of metformin prescribing in adults with type 2 diabetes mellitus: a national cross sectional study. *Pharmacotherapy* 2016;36:715-22.
- Wilhoite JE, Beggs AE, **Walton AM**. Evaluating student pharmacists' perceptions of medication adherence before and after a pillbox simulation. *Curr Pharm Teach Learn* 2016;8:634-9.

New ACCP Fellows

- **Joshua Caballero**
- **Sarah A. Nisly**

Other Notable Achievements

Emily Christenberry:

- Clinical Assistant Professor, UTEP School of Pharmacy, Department of Pharmacy Practice and Clinical Sciences.
- BCPS certification.

Beth Resman-Targoff: "Rheumatoid arthritis in the geriatric patient, secondary prevention, polypharmacy and challenges" and "Interprofessional case discussion." Invited talks at: Clinical Focus Course, Association of Rheumatology Health Professionals; November 12, 2016; Washington, DC.

Katie Traylor: BCACP and BC-ADM certification.

Presentations

- DePatis K, McLaughlin M, Kliethermes MA, Quinones-Boex A, **Kolanczyk D**, Schmidt J, Tran T, Vest KM. Factors influencing fourth year pharmacy student pursuit of research. Student poster presented at: ASHP Midyear Meeting; December 2016; Las Vegas, NV.
- Masic D, Greenhalgh E, **Kolanczyk DM**. Evaluation of appropriate prescribing of rivaroxaban and apixaban and clinical outcomes in a large academic medical center. Student poster presented at: 2016 ASHP Midyear Meeting; December 2016; Las Vegas, NV.

Emergency Medicine PRN

Awards

- **Katie Hiles:** Patient Hero Award for Sepsis in the ED. Indianapolis Coalition for Patient Safety, Franciscan Health Indianapolis.
- **Darrel W. Hughes:** Clinical Specialist, Emergency Medicine Pharmacy Residency Program Preceptor of the Year, University Health System.

Promotions

- **Hussain Bakhsh:** Assistant Professor, Clinical Pharmacy Department Faculty of Pharmacy, King Abdulaziz University.
- **Megan Musselman:** PGY1 Pharmacy Residency Coordinator, North Kansas City Hospital.
- **Ruben Santiago:** Associate Residency Program Director, PGY2 Emergency Medicine Pharmacy Residency Program, Jackson Memorial Hospital.
- **Jennifer Splawski:** Clinical Pharmacy Specialist – Emergency Medicine MacNeal Hospital.

Publications

- **Bailey AM**, Reed BS, **Weant KA**, **Justice SB**. Complements are not always a good thing: novel therapies for angioedema. *Adv Emerg Nurs J* 2016;38:93-108.
- **Bilhimer M**, **Treu CN**, **Acquisto NM**. Current practice of hypoglycemia management in the emergency department. *Am J Emerg Med* 2017;35:87-91.
- **Cavallari JM**, **Jawaro TS**, **Awad NI**, **Bridgeman PJ**. Glucagon for refractory asthma exacerbation. *Am J Emerg Med* 2017;35:144-5.
- **Hughes DW**. Critical care, fluids & electrolytes. In: Shapiro K, Brown S, eds. *RxPrep Course Book: 2017 ed.* RxPrep, 2017.
- Hodge EK, **Hughes DW**, Attridge RL. Effect of body weight on hemodynamic response in patients receiving fixed-dose vasopressin for septic shock. *Ann Pharmacother* 2016;50:816-23.
- **Kuroski JE**, Young S. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin. *Am J Emerg Med* 2017 Jan 24. [Epub ahead of print]
- **Metts EL**, **Bailey AM**, **Weant KA**, **Justice SB**. Identification of rate-limiting steps in the provision of thrombolytics for acute ischemic stroke. *J Pharm Pract* 2016. [Epub ahead of print]

- **Musselman M**, Pass S. Critical Care Preparatory Course: Toxicology. Lenexa, KS: American College of Clinical Pharmacy, 2017.
- Kattub H, Sterk E, **Rech MA**, Bukar B, Khan S. Early recognition and treatment of sepsis after the addition of lactate to critical laboratory call list. *J Intensive Care Med* 2016 Sep 11. [Epub ahead of print]
- Wong A, Erdman M, Hammond D, Holt T, Holzhausen J, Horng M, Huang LL, Jarvis J, Kram B, Kram S, Lesch C, Mercer J, **Rech MA**, Rivosecchi R, Stump B, Teevan C, Da S. Major publications in the critical care pharmacotherapy literature: January 2015 – December 2015. *Am J Health Syst Pharm* 2017;74:295-311.
- **Santiago RD**, Bazan JA, Brown NV, Adkins EJ, **Shirk MB**. Evaluation of pharmacist impact on culture review process for patients discharged from the emergency department. *Hosp Pharm* 2016;51:738-43.
- **Splawski J**, Horner D, Tao K. A survey of staff perceptions of an emergency medicine pharmacist program in a community hospital: a brief report. *Ann Emerg Med* 2017;69:308-14.
- **Splawski J**, Minger H. Value of the pharmacist in the medication reconciliation process. *P T* 2016;41:176-8.
- **Splawski J**, Minger H. The hospital pharmacist's utilization of the national patient safety goals to contribute to safe and effective medication use. In: *Drug Injury: Liability, Analysis, and Prevention*, 4th ed. Tucson: Lawyers & Judges Publishing.
- **Weant KA**, **Bailey AM**, Baum RA, **Justice SB**, **Calhoun CD**. Chemotherapy in the emergency department? There is a role for that: methotrexate for ectopic pregnancy. *Adv Emerg Nurs J* 2017;39:18-25.
- Bodkin RP, **Weant KA**, **Baker Justice S**, Spencer MT, **Acquisto NM**. Effectiveness of glucagon in relieving esophageal foreign body impaction: a multicenter study. *Am J Emerg Med* 2016;34:1049-52.
- McPheeters CM, VanArsdale VM, **Weant KA**. N-acetylcysteine use in non-acetaminophen-induced acute liver failure. *Adv Emerg Nurs J* 2016;38:183-9.
- **Wilson SS**, **Musselman M**. Intranasal and intraosseous routes of drug administration for drug delivery in the emergency department. In: Thomas M, ed. *Pharmacotherapy Self-Assessment Program. Science and Practice of Pharmacotherapy*. Lenexa, KS: American College of Clinical Pharmacy. In press.

New ACCP Fellows

- **Kyle Weant**: Emergency Medicine Clinical Specialist, Medical University of South Carolina.

Other Notable Achievements

- **William Eggleston**: President-Elect, New York State chapter, American College of Clinical Pharmacy.
- **Megan Musselman**: Emergency Neurological Life Support (ENLS) certification, Neurocritical Care Society.
- **Ruben Santiago**: Emergency Neurological Life Support (ENLS) certification, Neurocritical Care Society.

Endocrine and Metabolism PRN

Publications

- **Fazel MT**, Erstad BL. Step VI: maximize experiential education. In: *The ACCP Field Guide to Becoming a Standout Pharmacy Residency Candidate*, 2nd ed. Lenexa, KS: American College of Clinical Pharmacy, 2016:91-114.
- **Fazel MT**, Fazel M, Bedrossian NL, Picazo F, Pendergrass ML. A student-implemented elective to improve medical student confidence in providing diabetes self-management support. *Adv Med Educ Pract* 2016;7:567-70.
- **Fazel MT**, Pendergrass ML. Individualizing treatment of hyperglycemia in type 2 diabetes. *JCOM* 2017;24:23-38.
- **Fazel MT**, Waterbrook A, Alfayez O, Pendergrass M. Novel strategy to increase insulin initiation in the emergency department (ED). *ACCP Annual Meeting Abstracts. Pharmacotherapy* 2016;36:e228-9.
- **Pastakia SD**, Manyara SM, Vedanthan R, Kamano JH, Menya D, Andama B, Chesoli C, Laktabai J. Impact of bridging income generation with group integrated care (BIGPIC) on hypertension and diabetes in rural western Kenya. *J Gen Intern Med* 2016 Dec 5. [Epub ahead of print]
- Barasa FA, Vedanthan R, **Pastakia SD**, Crowe SJ, Aruasa W, Sugut WK, White R, Ogola ES, Bloomfield GS, Velazquez EJ. Approaches to sustainable capacity building for cardiovascular disease care in Kenya. *Cardiol Clin* 2017;35:145-52.
- Kanyi J, Karwa R, **Pastakia SD**, Manji I, Manyara S, Saina C. Venous thromboembolism requiring extended anticoagulation among HIV-infected patients in a rural, resource-constrained setting in western Kenya. *Ann Pharmacother* 2016 Dec 1.

- O'hara EG, Kirui NK, **Pastakia SD**, et al. Characteristics of a diabetes cohort in rural western Kenya. *Lancet Diabetes Endocrinol* 2016 Jun 22.
- Tran DN, Njuguna B, Mercer T, Manji I, Fischer L, Lieberman M, **Pastakia SD**. Ensuring patient-centered access to cardiovascular disease medicines in low-income and middle-income countries through health system strengthening. *Cardiol Clin* 2017;35:125-34.
- **Rizvi A**, Castro G, Madison C. Impact of student-led medication review on adherence and comprehension of medication therapy in geriatric patients. *Medicine (Baltimore)* 2015;94:e1805.
- Burke K, **Schumacher C**, Harpe S. SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in primary literature. *Pharmacotherapy*. Accepted for publication.
- Phillips J, **Schumacher C**, Arif S. Measuring time spent, workload and student and faculty perceptions when implementing a blended learning environment in a college of pharmacy. *Am J Pharm Educ* 2016;80:102.
- **Singh-Franco D**, Harrington C, Tellez-Corrales E. An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease. *SAGE Open Med* 2016;4:1-16.
- **Singh-Franco D**, Jacobs RJ. Patient perspectives on peripheral neuropathic pain experience within the community. *Diabetes Metab Syndr Clin Res Rev* 2016. <http://dx.doi.org/10.1016/j.dsx.2016.12.038>.
- Lisenby KM, Meyer A, **Slater NA**. Is an SGLT2 inhibitor right for your patient with type 2 diabetes? *J Fam Pract* 2016;65:587-93.
- Rushakoff RJ, Mary M. Sullivan MM, **Windham MacMaster H**, Shah AD, Rajkomar A, Kohn MA. Association between a virtual glucose management service and glycemic control in hospitalized adult patients. *Ann Intern Med* 2017.

Other Notable Achievements

- **Krystal Edwards**: Associate Dean of Career Development, Texas Tech School of Pharmacy – DFW campus.
- **Maryam Fazel**: American College of Clinical Pharmacy Ambulatory Care PRN 2016 Member Recognition Award.
- **Benjamin Gross**: ASH-CHC (American Society of Hypertension Certified Hypertension Clinician) certification.

- **Vasudha Gupta**: CDE certification.
- **Craig Logemann**: President-Elect, Iowa Pharmacy Association.
- **Sonak Pastakia**: Jefferson Science Fellowship.

Anum Rizvi:

- ASHP Clinical Skills Competition Winner: First Place (Roseman University of Health Sciences), September 2016.
- American College of Clinical Pharmacy Clinical Pharmacy Challenge Runner-up (Roseman University of Health Sciences), October 2016.
- Roseman University Leadership Scholarship (\$1250), January 2017.
- **Christie Schumacher**: Expert Reviewer, Pharmacotherapy Self-Assessment Program (PSAP) 2017 Book 1 (Endocrinology/Nephrology).
- **Jordan Sedlacek**: BCACP certification.
- **Heidemarie Windham MacMaster**: The only pharmacist among the 53 authors of *Managing Diabetes and Hyperglycemia in the Hospital Setting, a clinician's guide*.

Kim Kelly:

- Updated both Certified Professional Coder credential with ICD-10 Certification and Certified Endocrine Coder credential
- Conducted a webinar on Basal Bolus Insulin Therapy and another on Landmark Clinical Trials in Diabetes, both for the J&J Diabetes Institute

S. Mimi Mukherjee:

- Certified Diabetes Educator (CDE)
- Sequential remediation in a pharmacotherapeutics course series. Poster presented as first author at: American Association of Colleges of Pharmacy (AACCP) Annual Meeting; July 2016.
- **Kavita Parikh**: Pharmacy Quality Alliance - CVS Health Foundation Scholar
- **Krystal Riccio**: Certified Diabetes Educator (CDE)

Presentations

- **Christie Schumacher**: Expanding pharmacy impact: transitional care management and chronic care management. Presented at: American College of Clinical Pharmacy Annual Meeting; October 2016; Hollywood, FL.

Poster Presentations

- **Fazel MT**, Waterbrook A, Alfayez O, Pendergrass M. Novel strategy to increase insulin initiation in the

emergency department (ED). Presented at: 2016 American College of Clinical Pharmacy Annual Meeting; October 2016; Hollywood, FL.

- Alshehri AA, **Fazel MT**, Slack MK, Valencia J. Joint pharmacist-physician patient visits billing model and its impact on reimbursement. Presented at: ASHP Midyear Meeting; December 2016; Las Vegas, NV.
- Roman M, **Rizvi A**, Chang D, Madison C. Evaluating the outcome of pharmacy speaker events on student perceptions of the evolving role of pharmacists. Poster presented at: Third Annual Roseman University of Health Sciences Research Symposium; March 2017; Henderson, NV.
- Eltaki SM, **Singh-Franco D**, Jarvis H, Leon D, Nguyen M, Calix M, Wolowich W. Adopting transitions of care within the doctor of pharmacy curriculum. Poster presented at: American College of Clinical Pharmacy Annual Meeting; October 2016; Hollywood, FL.

Geriatrics PRN

Promotions

- **Tiffany Hopkins**: Faculty Appointment, University of North Texas.
- **Reem A. Lhaj**: Kaiser Permanente Pharmacist.

Awards

- **Margaret Noyes Essex**: 2016 American College of Clinical Pharmacy Virtual Symposium, AmCare Best Poster Award.
- **Tiffany Hopkins**: **2016 ASCP Feldman Scholarship**.
- **Jeannie K. Lee**: University of Arizona Academic Leadership Institute, 2016.
- **Emily Peron**: VCU Center for Interprofessional Education and Collaborative Care Emerging Leader in Interprofessionalism.
- **Heather Sakely**: Practice Change Leaders Program.

Grants

- **Lisa Hutchison**: National Center for Interprofessional Practice and Education. Project: Accelerating Interprofessional Community-Based Education and Collaboration for Older Persons with Mental Health Disparities.

Jeannie Lee:

- National Science Foundation at Arizona Tech Launch I-Corps. Project: Medication Education

Decision Support Reminding and Monitoring (MEDSRem).

- Banner Health Innovations Grant. Project: Supporting Function in At-Risk Elders: Early Identification of Frailty in an Ambulatory Setting.

Publications

- Kostoff M, **Burkhardt C**, Winter A, Shrader S. An interprofessional simulation using the SBAR communication tool. *Am J Pharm Educ* 2016;80:Article 157.
- **Essex MN**, Cheung R, Li C. The effects of parecoxib on movement-related pain following major gynecological surgery. Presented at: Euroanaesthesia 2016; May 2016; London, UK. Published in: *Eur J Anaesthesiol* 2016;33:e-Supplement 54.
- **Essex MN**, Cheung R, Li C, Xie L. Safety of greater than 3 days of therapy with parecoxib injection in the management of postoperative pain. 2016 American College of Clinical Pharmacy Virtual Poster Symposium; May 2016.
- **Essex MN**, Hopps M, Bienen EJ, Udall M, Mardekian J, Makinson GT. Evaluation of the relationship between serum uric acid levels and cardiovascular events in patients with gout: a retrospective analysis using electronic medical record data. *J Clin Rheum* 2017. [Epub ahead of print]
- **Essex MN**, Schug S, Parsons B, Li C, Xia F, Cheung R. The safety profile of parecoxib for the treatment of post-operative pain: an examination of over 10 years of post-authorization safety data. Presented at: Euroanaesthesia 2016; May 2016; London, UK. Published in: *Eur J Anaesthesiol* 2016;33:e-Supplement 54.
- Burke CA, Phillips R, Berger M, Li C, **Essex MN**, Iorga D, Lynch PM. Children's International Polyposis (CHIP) study: a randomised, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis. *J Clin Exper Gastroenterol*. Accepted for publication.
- Diaz-Borjon, E, Torres-Gomez A, **Essex MN**, Salomon P, Li C, Cheung R, Parsons B. Parecoxib provides analgesic and opioid-sparing effects following major orthopedic surgery: a subset analysis of a randomized, placebo-controlled clinical trial. *Pain Ther* 2017. [Epub ahead of print]
- Walker C, **Essex MN**, Li C, Park PW. Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: a 12-week randomized study in Norwegian patients. *J Int Med Res* 2016;44:483-95.

- Brown J, **Hutchison LC**, Li CH, Painter JT, Martin BC. Predictive validity of the Beers and STOPP criteria to detect adverse drug events, hospitalizations, and emergency department visits in the United States. *J Am Geriatr Soc* 2016;64:22-30.
- **Lam S**. Urinary incontinence and pediatric enuresis. In: Chisholm-Burns MA, Schwinghammer TL, Wells BG, et al., eds. *Pharmacotherapy Principles & Practice*, 4th ed. New York: McGraw-Hill, 2016:811-28.
- Rovner, ES, Wyman J, **Lam S**. Urinary incontinence. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. *Pharmacotherapy: A Pathophysiologic Approach*, 10th ed. New York: McGraw-Hill, 2016:1353-72.
- Cioltan H, Alshehri S, Howe C, **Lee J**, Fain M, Eng H, Schachter K, Mohler J. Variation in use of antipsychotic medications in nursing homes in the United States: a systematic review. *BMC Geriatr* 2017;17:32-44.
- **Lee JK**. ASHP Geriatric Pharmacy Literature Study 2016, Module 1A: New Beers Criteria. ASHP Geriatric Review Course Recertification. Available at eLearning.ashp.org. September 2016.
- **Lee JK**. Elder care: a resource for interprofessional providers: depression in older adults—pharmacotherapy. Portal of Geriatrics Online Education (POGOe). Available at www.pogoe.org/productid/20894. September 2016.
- **Lee JK**, Mahvan T, Neipris L, Levy JS. R1036: a 76-year-old man with multiple medical problems and acute symptoms [Internet]. Newtown Square, PA: CaseNetwork, October 2016. Available at <http://cases.casenet.com>.
- **Lee JK**, Shaw SJ, Huebner Torres CI, Korchmaros JD, Totman M. Creative partnership to assess health beliefs, health literacy and medication adherence among ethnically diverse populations. *Am J Pharm Educ* 2016;80:Article S2:102-3.
- Zhou R, Vaughn C, Wong W, **Lee JK**. Assessing an interactive approach to educate older adults and caregivers on Alzheimer's disease. *J Am Geriatr Soc* 2016;64(suppl 1):S224.
- **Noyes MN**. Investigator-initiated research. In: *Essentials of the Pharmaceutical Industry for Health Care Professionals*. Pfizer, 2016:20-3.
- **Peron EP**, Ogbonna KC. Medication reviews in older adults. In: Stegemann S, ed. *Developing Drug Products in an Aging Society: From Concept to Prescribing*. American Association of Pharmaceutical Scientists Advances in the

Pharmaceutical Sciences Series. Switzerland: Springer, 2016.

- **Peron EP**, Slattum PW, Powers KE, Hobgood SE. Alzheimer disease. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. *Pharmacotherapy: A Pathophysiologic Approach*, 10th ed. New York: McGraw-Hill, 2017.
- Rubin SE, Gendron TL, **Peron EP**. Reciprocity and shared experiences through transgenerational creative arts. *Public Pol Aging Rep* 2016;26:111-3.
- **Vouri SM**, Chung JM, Binder EF. Successful intervention to mitigate an acetylcholinesterase inhibitor-induced rhinorrhea prescribing cascade: a case report. *J Clin Pharm Ther* 2017. In press.
- **Vouri SM**, Kebodeaux CD, Stranges PM, Teshome BF. Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: a systematic review and meta-analysis. *Arch Gerontol Geriatr* 2017;69:77-96.
- Stranges PM, **Vouri SM**. Impact of resident research publication on early-career publication success. *Am J Health Syst Pharm* 2016;73:895-900.

Other Notable Achievements

- **Crystal Burkhardt, Angela Livingood, and Lori Miyashiro**: CGP certification.
- **Margaret Noyes Essex**: NYU and Weill Cornell Pharmaceutical Medicine Elective Steering Committee member.
- **Haley Phillippe**: BCPS certification.

Presentations

- **Jack Chen, Kitty Chu, and Stephanie (Seaton) Crist**: Posters presented at: 2016 American College of Clinical Pharmacy Annual Meeting; October 2016; Hollywood, FL.
- **Lam S**. Community outreach programs to enhance health knowledge in the elderly. Presented at: American College of Clinical Pharmacy Annual Meeting; October 2016; Hollywood, FL.
- James S, **Lam S**. Use of melatonin receptor agonists in patients with delirium. Presented at: ASHP Midyear Meeting; December 2016; Las Vegas, NV.
- Nieves S, **Lam S**. Evaluation of oral iron replacement therapy in geriatric patients. Eastern States Residency Conference; May 2016; Hershey, PA.
- Yunusova T, Cummings C, **Lam S**. Pharmacy students' perception of taking Drug Induced

Diseases Course before vs. after experiential clinical rotations. Presented at: ASHP Midyear Meeting; December 2016; Las Vegas, NV.

Jeannie Lee:

- Steps to a good night's sleep. In: University of Arizona Health Sciences blog. <http://uahs.arizona.edu/blog/2016-03-17/steps-good-night%E2%80%99s-sleep>. March 2016.
- Medications and falls. In: Pima County Health Department Fall Prevention Week Series by KGUN9 Morning Blend. <https://youtu.be/7KjT-zZAE-w>. September 2016.
- Reducing fragility fractures in the elderly population. Pharmacy Practice News, Clinical Section. www.pharmacypracticenews.com/Clinical/Article/11-16/Reducing-Fragility-Fractures-in-the-Elderly-Population/38607. November 2016.
- Bad medicine: problems plague those with several prescriptions. Green Valley News Featured Article. www.gvnews.com/news/bad-medicine-problems-plagu-those-with-several-prescriptions/article_f6f2333a-c78f-11e6-9e02-4bec2a104828.html. December 2016.

GI/Liver/Nutrition PRN

The GILN PRN would like to congratulate its members on the following accomplishments from September 2016 to February 2017.

Awards

Charles F. Seifert:

- 2015–2016 TTUHSC School of Pharmacy P3 Teacher of the Year
- 2016 TTUHSC Student Government Association School of Pharmacy Outstanding Didactic Teacher of the Year

Grants

- **Kelsey Rife:** Hepatitis C Innovation Team Grant. \$200,000. Funded by VA HIT Collaborative.

Publications

- **Martin MT.** Gastrointestinal disorders. In: Bainbridge JL, Cardone K, Cross LB, et al., eds. Updates in Therapeutics[®]: Ambulatory Care Pharmacy Preparatory Review and Recertification Course, 2017 ed. Lenexa, KS: American College of Clinical Pharmacy, 2017:597-708.

- **Martin MT, Faber DM.** Patient satisfaction with the clinical pharmacist and prescribers during hepatitis C virus management. *J Clin Pharm Ther* 2016;41:645-9.
- Kostadinova L, Shive C, Judge C, Zebrowski E, Compan A, **Rife K**, et al. During HCV and HCV-HIV infection elevated plasma autotaxin is associated with LPA and markers of immune activation that normalize during IFN-free HCV therapy. *J Infect Dis* 2016;214:1438-48.
- Rambaran KA, **Seifert CF.** Unrecognized interstitial lung disease as a result of chronic nitrofurantoin use. *Drug Saf Case Rep* 2016;3:13.
- Rodriguez AI, Zupancic S, Song, MM, Cordero J, Nguyen TQ, **Seifert CF.** Importance of an Interprofessional team approach in achieving improved management of the dizzy patient. *J Am Acad Audiol* 2017. In press.
- Samuel NG, **Seifert CF.** Risk of bleeding in patients on full-dose enoxaparin with venous thromboembolism and selective serotonin reuptake inhibitors. *Ann Pharmacother* 2016;50:1-6.

Presentations

- **Deming P, Martin MT, Rife K.** Hepatitis C virus: the newest strategies for management and treatment. CPE presented at: ACCP 2016 Clinical Reasoning Series. Material also offered as a webinar. October 22, 2016; Hollywood, FL.
- **Martin MT.** Updates on gastrointestinal disorders. CPE presented at: ACCP Updates in Therapeutics[®] 2017 Ambulatory Care Preparatory Review and Recertification Course; February 18, 2017; Jacksonville, FL.
- **Martin MT.** The future of HCV management for managed care: differentiating therapy by patient characteristics. CE presented for: PRIME at the Academy of Managed Care Pharmacy (AMCP) Ohio-Kentucky Chapter Meeting; September 20, 2016; West Chester, OH.
- **Martin MT.** Optimizing HCV treatment continuity and outcomes: empowering pharmacists to take action. CPE presented at: Pharmacy Learning Network Regional Meeting; March 4, 2017; Orange County, CA.
- **Rife K.** Applications of telehealth and lean six sigma to hepatitis C. Presented at: Cleveland Society of Pharmacy Residents; October 2016; Cleveland, OH.

Poster Presentations

- LeClerc S, Pascuzzi K, Falck-Ytter C, Falck-Ytter Y, Burant C, **Rife K**. Viral response to hepatitis C direct-acting antivirals significantly improves diabetes control. AASLD; 2016.
- Lyman A, Falck-Ytter Y, Falck-Ytter C, Pascuzzi K, Burant C, **Rife K**. The impact of achieving virologic response from hepatitis C direct-acting antivirals on diabetes control. Presented at: ASHP Midyear Meeting; December 2016; Las Vegas, NV.

Other Notable Achievements

- **Steve Polgsted**: Chair-Elect, Pediatric Section of ASPEN.

Global Health PRN

Our PRN has been creating connection opportunities for our members! We recently started an [ACCP Global Health PRN Facebook page](#): feel free to “like” us!

Our PRN has also started a mentor/mentee program to facilitate mentorship for those interested in pursuing global health activities. So far, six pairs of mentors/mentees have signed up to be part of the program.

Our founder and past chair, Renee Holder, recently died. She was passionate about the ACCP Global Health PRN; therefore, we wanted to commemorate her efforts through a memorial travel award for our members in her honor. Applications for the award open soon, and the award recipient will be notified before the October 2017 ACCP Annual Meeting.

Our newsletter is off to a great start! So far, we've developed two newsletters, with three future newsletters slated for the rest of 2017. The newsletter is composed of spotlight sections on pharmacists and students, global health news from other organizations, and a country spotlight.

Awards

- **Sonak Pastakia**: Jefferson Science Fellowship.
- **Emily Peron**: VCU Global Education Office Quest Global Impact Award.

Publications

- **Pastakia SD**, Manyara SM, Vedanthan R, Kamano JH, Menya D, Andama B, Chesoli C, Laktabai J. Impact of bridging income generation with group integrated care (BIGPIC) on hypertension and diabetes in rural western Kenya. *J Gen Intern Med* 2016 Dec 5. [Epub ahead of print]
- Barasa FA, Vedanthan R, **Pastakia SD**, Crowe SJ, Aruasa W, Sugut WK, White R, Ogola ES, Bloomfield GS, Velazquez EJ. Approaches to

sustainable capacity building for cardiovascular disease care in Kenya. *Cardiol Clin* 2017;35:145-52.

- Kanyi J, Karwa R, **Pastakia SD**, Manji I, Manyara S, Saina C. Venous thromboembolism requiring extended anticoagulation among HIV-infected patients in a rural, resource-constrained setting in western Kenya. *Ann Pharmacother* 2016 Dec 1.
- O'hara EG, Kirui NK, **Pastakia SD**, et al. Characteristics of a diabetes cohort in rural western Kenya. *Lancet Diabetes Endocrinol* 2016 Jun 22.
- Tran DN, Njuguna B, Mercer T, Manji I, Fischer L, Lieberman M, **Pastakia SD**. Ensuring patient-centered access to cardiovascular disease medicines in low-income and middle-income countries through health system strengthening. *Cardiol Clin* 2017;35:125-34.

New ACCP Fellows

- Sonak Pastakia

Health Outcomes PRN

Promotions

- **Bonnie C. Greenwood**: Assistant Professor, Department of Family Medicine and Community Health, School of Medicine, University of Massachusetts.
- **Hannah M. Renner**: Fellow in Community Pharmacy Research, University of Pittsburgh School of Pharmacy.

Grants

- **William L. Baker**: AHRQ Grant \$355,000: Pharmacologic Management of Asthma. Role: Coinvestigator.

Publications

- McEvoy DS, Sittig DF, Hickman TT, Aaron S, Ai A, **Amato M**, Bauer DW, Fraser GM, Harper J, Kennemer A, Krall MA, Lehmann CU, Malhotra S, Murphy DR, O'Kelley B, Samal L, Schreiber R, Singh H, Thomas EJ, Vartian CV, Westmorland J, McCoy AB, Wright A. Variation in high-priority drug-drug interaction alerts across institutions and electronic health records. *J Am Med Inform Assoc* 2017;24:331-8.
- **Amato MG**, Salazar A, Hickman TT, Quist AJL, Volk L, Wright A, McEvoy D, Slight SP, Bates DW, Schiff GD. Computerized prescriber order entry (CPOE) related patient safety reports: analysis of 2522 errors. *J Am Med Inform Assoc* 2017;24:316-22.

- Her QL, **Amato MG**, Seger DL, Gilmore JF, Fanikos J, Fiskio JM, Bates DW. Review of non-formulary medication (NFM) approvals in an academic medical center. *Jt Comm Jnl Qual Saf* 2017;43:89-96.
- Wong A, **Amato MG**, Seger DL, Slight SP, Beeler PE, Dykes PC, Fiskio JM, Orav EJ, Eguale T, Silvers ER, Bates DW. Evaluation of medication-related clinical decision support alert overrides in the intensive care unit. *J Crit Care* 2017.
- **Baker WL**. Treating arrhythmias with adjunctive magnesium: identifying future research directions. *Eur Heart J Cardiovasc Pharmacother* 2016 Sep 15 [Epub ahead of print]
- **Baker WL**, Coleman CI. Vitamin C for prevention of post-cardiothoracic surgery atrial fibrillation: a meta-analysis. *Am J Health Syst Pharm* 2016;73:2056-66.
- **Baker WL**, Darsaklis K, Singhvi A, Salerno EL. Selexipag, an oral prostacyclin-receptor agonist for pulmonary arterial hypertension. *Ann Pharmacother*. In press.
- Jennings DL, **Baker WL**. Pre-cardiac transplant amiodarone use is not associated with postoperative mortality: an updated meta-analysis. *Int J Cardiol*. In press.
- Vu V, **Baker WL**, Tcenza EM, Tessier ND, Rochon C, Sheiner PA, Marter ST. Intravenous acetaminophen for postoperative pain management in patients undergoing living donor nephrectomy. *Ann Pharmacother* 2016 Sep 8. [Epub ahead of print]
- Weeda ER, Nicoll BS, Coleman CI, Sharovetskaya A, **Baker WL**. Association between weekend admission and in-hospital mortality for variceal and nonvariceal upper gastrointestinal hemorrhage: an observational study and meta-analysis. *Int Emerg Med* 2016 Aug 17. [Epub ahead of print]
- Weymann A, Sabashnikov A, Ali-Hassan-Sayegh S, Popov AF, Mirhosseini SJ, **Baker WL**, et al.; for the Integrated Meta-analysis of Cardiac Surgery and Cardiology Group (IMCSC-Group). Predictive role of coagulation, fibrinolytic, and endothelial markers in patients with atrial fibrillation, stroke and thromboembolism: a meta-analysis, meta-regression and systematic review. *Med Sci Monit Basic Res*. In press.

Other Notable Achievements

- **William L. Baker**: Fellow, American Heart Association.

Hematology/Oncology PRN

- Ogunniyi A, Rodriguez M, Devlin S, **Adel N**, Landau H, Chung DJ, Lendvai N, Lesokhin A, Koehne G, Mailankody S, Korde N, Reich L, Landgren O, Giral S, Hassoun H. Upfront use of plerixafor and granulocyte-colony stimulating factor (G-CSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency. *Leuk Lymphoma* 2017;58:1123-9.
- Reiss SN, Buie LW, **Adel N**, Goldman DA, Devlin SM, Douer D. Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. *Ann Hematol* 2016;95:2009-15.
- **Afifi S**, Michael A, Lesokhin A. Immunotherapy: a new approach to treating multiple myeloma with daratumumab and elotuzumab. *Ann Pharmacother* 2016;50:555-68.
- Prasad V, Wang R, **Afifi SH**, Mailankody S. The rising price of cancer drugs—a new old problem? *JAMA Oncol* 2016 Oct 6.
- Worrall CL, **Aistrope DS**, Cardello EA, Fulginiti KS, Jordan RP, Martin SJ, McGrath K, Park SK, Shepler B, Whalen K, Bradley-Baker LR. Priming the preceptor pipeline: collaboration, resources, and recognition: the report of the 2015-2016 Professional Affairs Standing Committee. *Am J Pharm Educ* 2016;80:S19.
- Aljadhey H, Mahmoud MA, Alshammari TM, **Al-Dhaeefi M**, Le Louet H, Perez-Gutthann S, Pitts PJ. A qualitative exploration of the major challenges facing pharmacovigilance in Saudi Arabia. *Saudi Med J* 2015;36:1097-102.
- El Hajj MS, Awaisu A, Saleh RA, **Alhamad NM**, Kheir N, Zeenny R, Fathelrahman A. Tobacco-related education in schools of pharmacy in the Middle East: a multinational cross-sectional study. *Nicotine Tob Res* 2017 Feb 6.
- **Aloi J**, Bode BW, Ullal J, Chidester P, McFarland RS, Bedingfield AE, Mabrey M, Booth R, Mumpower A, Wallia A. Comparison of an electronic glycemic management system versus provider-managed subcutaneous basal bolus insulin therapy in the hospital setting. *J Diabetes Sci Technol* 2017;11:12-6.
- Ullal J, McFarland R, Bachand M, **Aloi J**. Use of a computer-based insulin infusion algorithm to treat diabetic ketoacidosis in the emergency department. *Diabetes Technol Ther* 2016;18:100-3.

- Bleyer AJ, **Aloi JA**. Sick cell trait and interpretation of hemoglobin A1c levels. *JAMA* 2017;317:481-2.
- Gorris MA, Arora H, Lieb DC, **Aloi JA**. A word of caution when prescribing high-dose vitamin D. *Am J Med* 2016 Nov 25.
- Gorris MA, Guido MV, Rawla MS, **Aloi JA**. Parathyroid hemorrhage. *J Emerg Med* 2017 Mar 1.
- Abolfotouh MA, **AlQarni AA**, Al-Ghamdi SM, Salam M, Al-Assiri MH, Balkhy HH. An assessment of the level of concern among hospital-based health-care workers regarding MERS outbreaks in Saudi Arabia. *BMC Infect Dis* 2017;17:4.
- **Bakri MH**, Ismail EA, Abd-Elshafy SK. Analgesic effect of nalbuphine when added to intravenous regional anesthesia: a randomized control trial. *Pain Physician* 2016;19:575-81.
- **Barreto JN**, Ice LL, Thompson CA, Tosh PK, Osmon DR, Dierkhising RA, Plevak MF, Limper AH. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy. *Am J Hematol* 2016;91:1113-7.
- Durani U, Dioverti Prono MV, Tosh PK, Patnaik M, **Barreto JN**, Tande AJ. Influenza infection in neutropenic adults. *Infect Dis (Lond)* 2017;49:141-6.
- Frazee E, Rule AD, Lieske JC, Kashani KB, **Barreto JN**, Virk A, Kuper PJ, Dierkhising RA, Leung N. Cystatin C-guided vancomycin dosing in critically ill patients: a quality improvement project. *Am J Kidney Dis* 2017 Jan 25.
- Leung JG, Hasassri ME, **Barreto JN**, Nelson S, Morgan RJ III. Characterization of admission types in medically hospitalized patients prescribed clozapine. *Psychosomatics* 2016 Nov 18.
- **Bell GC**, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, Gaedigk A, Agundez JA, Sadhasivam S, Klein TE, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. *Clin Pharmacol Ther* 2016 Dec 21.
- Dunnenberger HM, Biszewski M, **Bell GC**, Sereika A, May H, Johnson SG, Hulick PJ, Khandekar J. Implementation of a multidisciplinary pharmacogenomics clinic in a community health system. *Am J Health Syst Pharm* 2016;73:1956-66.
- Knepper TC, **Bell GC**, Hicks JK, Padron E, Teer JK, Vo TT, Gillis NK, Mason NT, McLeod HL, Walko CM. Key Lessons learned from Moffitt's Molecular Tumor Board: the Clinical Genomics Action Committee experience. *Oncologist* 2017;22:144-51.
- Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, **Bookout R**, Nieder M, Khaira DK, Davila M, Alsina M, Field T, Ayala E, Locke FL, Riches M, Kharfan-Dabaja M, Fernandez H, Anasetti C. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. *Haematologica* 2017 Jan 19.
- El-Asmar J, Gonzalez R, **Bookout R**, Mishra A, Kharfan-Dabaja MA. Clotrimazole troches induce suprathreshold blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury. *Hematol Oncol Stem Cell Ther* 2016;9:157-61.
- Palmer J, McCune JS, Perales MA, Marks D, **Bubalo J**, Mohty M, Wingard JR, Paci A, Hassan M, Bredeson C, Pidala J, Shah N, Shaughnessy P, Majhail N, Schriber J, Savani BN, Carpenter PA. Personalizing busulfan-based conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. *Biol Blood Marrow Transplant* 2016;22:1915-25.
- Pham AN, **Bubalo JS**, Lewis JS II. Posaconazole tablet formulation at 400 milligrams daily achieves desired minimum serum concentrations in adult patients with a hematologic malignancy or stem cell transplant. *Antimicrob Agents Chemother* 2016;60:6945-7.
- Bates JS, **Buie LW**, Amerine LB, Savage SW, Eckel SF, Patel R, Valgus JM, Rao K, Daniels R. Expanding care through a layered learning practice model. *Am J Health Syst Pharm* 2016;73:1869-75.
- Horvat TZ, Pecoraro JJ, Daley RJ, **Buie LW**, King AC, Rampal RK, Tallman MS, Park JH, Douer D. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance. *Leuk Res* 2016;50:17-20.
- Reiss SN, **Buie LW**, Adel N, Goldman DA, Devlin SM, Douer D. Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. *Ann Hematol* 2016;95:2009-15.
- Deal EN, Stranges PM, Maxwell WD, Bacci J, Ashjian EJ, **DeRemer DL**, Kane-Gill SL, Norgard NB, Dombrowski L, Parker RB. The importance of research and scholarly activity in pharmacy training. *American College of Clinical Pharmacy. Pharmacotherapy* 2016;36:e200-5.
- Holle LM, Harris CS, Chan A, **Fahrenbruch RJ**, Labdi BA, Mohs JE, Norris LB, Perkins J, Vela CM. Pharmacists' roles in oncology pharmacy services:

results of a global survey. *J Oncol Pharm Pract* 2016 Feb 6.

- He Y, Huang H, Farischoon C, Li D, Du Z, Zhang K, Zheng X, **Goodin S**. Combined effects of atorvastatin and aspirin on growth and apoptosis in human prostate cancer cells. *Oncol Rep* 2017;37:953-60.
- Wu B, Lewis LD, **Harvey RD**, Rasmussen E, Gamelin E, Sun YN, Friberg G, Koyner JL, Dowlati A, Maitland ML. A pharmacokinetic and safety study of trebananib, a Fc-fusion peptibody, in patients with advanced solid tumors and varying degrees of renal dysfunction. *Clin Pharmacol Ther* 2017 Jan 11.
- **Hayes SM**, Wasko JA, Warlick ED. Clofarabine desensitization: a case report. *Leuk Res Rep* 2017. <http://dx.doi.org/10.1016/j.lrr.2017.02.001>.
- Hammond DA, Smith MN, Li C, **Hayes SM**, Lusardi K, Bookstaver PB. Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. *Clin Infect Dis* 2017. <https://doi.org/10.1093/cid/ciw811>.
- Patel JM, **Holle LM**, Clement JM, Bunz T, Niemann C, Chamberlin KW. Impact of a pharmacist-led oral chemotherapy-monitoring program in patients with metastatic castrate-resistant prostate cancer. *J Oncol Pharm Pract* 2016;22:777-83.
- **Huang L**, Fernandes H, Zia H, Tavassoli P, Rennert H, Pisapia D, Imielinski M, Sboner A, Rubin MA, Kluk M, Elemento O. The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations. *J Am Med Inform Assoc* 2016 Oct 27.
- Jacobs C, Clemons M, Mazzarello S, Hutton B, Joy AA, Brackstone M, Freedman O, Vandermeer L, **Ibrahim M**, Fergusson D, Hilton J. Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients. *Support Care Cancer* 2017 Jan 27.
- Mahmoud S, **Ibrahim M**, Hago A, Huang Y, Wei Y, Zhang J, Zhang Q, Xiao Y, Wang J, Adam M, Guo Y, Wang L, Zhou S, Xin B, Xuan W, Tang J. Overexpression of sulfatase-1 in murine hepatocarcinoma Hca-F cell line downregulates mesothelin and leads to reduction in lymphatic metastasis, both in vitro and in vivo. *Oncotarget* 2016;7:75052-63.
- Ogunleye F, **Ibrahim M**, Allen E, Brennan N, Huang J, Yu Z, Huben M, Jaiyesimi I. BCR-ABL testing by polymerase chain reaction in patients with neutrophilia: the William Beaumont Hospital Experience and the case for rational laboratory test requests. *J Oncol Pharm Pract* 2016;12:e1001-5.
- **Ice LL**, Barreto JN, Dao BD, Wolf RC, Dierkhising RA, Jannetto PJ, Langman LJ, Tosh PK. Relationship of sulfamethoxazole therapeutic drug monitoring to clinical efficacy and toxicity: a retrospective cohort study. *Ther Drug Monit* 2016;38:319-26.
- Barreto JN, **Ice LL**, Thompson CA, Tosh PK, Osmon DR, Dierkhising RA, Plevak MF, Limper AH. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy. *Am J Hematol* 2016;9:1113-7.
- **Ignoffo R**, Knapp K, Barnett M, Barbour SY, D'Amato S, Iacovelli L, Knudsen J, Koontz SE, Mancini R, McBride A, McCauley D, Medina P, O'Bryant CL, Scarpace S, Stricker S, Trovato JA. Board-certified oncology pharmacists: their potential contribution to reducing a shortfall in oncology patient visits. *J Oncol Pharm Pract* 2016;12:e359-68.
- Bejanyan N, Rogosheske J, DeFor TE, Lazaryan A, Arora M, Holtan SG, **Jacobson PA**, MacMillan ML, Verneris MR, Blazar BR, Weisdorf DJ, Wagner JE, Brunstein CG. Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free graft-versus-host disease prophylaxis for reduced-intensity conditioning umbilical cord blood transplantation. *Biol Blood Marrow Transplant* 2016;22:2025-30.
- Wasko JA, Westholder JS, **Jacobson PA**. Rifampin-sirolimus-voriconazole interaction in a hematopoietic cell transplant recipient. *J Oncol Pharm Pract* 2017;23:75-9.
- Kyriakopoulos CE, Braden AM, **Kolesar JM**, Eickhoff JC, Bailey HH, Heideman J, Liu G, Wisinski KB. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. *Invest New Drugs* 2016 Dec 21. [Epub ahead of print]
- Nikolinakos PG, **Kolesar JM**, Kuhn JG, Sportelli P, Miskin HP, O'Connor OA. A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. *Br J Haematol* 2017 Feb 21.
- Sawas A, Farber CM, Schreeder MT, Khalil MY, Mahadevan D, Deng C, Amengual JE, Becher OJ, Gilheeny SW, Khakoo Y, Lyden DC, Haque S, De Braganca KC, **Kolesar JM**, Huse JT, Modak S, Wexler LH, Kramer K, Spasojevic I, Dunkel IJ. A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. *Pediatr Blood Cancer* 2016 Dec 30. [Epub ahead of print]

- Sippy R, **Kolesar JM**, Darst BF, Engelman CD. Prioritization of family member sequencing for the detection of rare variants. *BMC Proc* 2016;10(suppl 7):227-31.
- Anchordoquy TJ, Barenholz Y, Boraschi D, Chorny M, Decuzzi P, Dobrovolskaia MA, Farhangrazi ZS, Farrell D, Gabizon A, Ghandehari H, Godin B, **La-Beck NM**, Ljubimova J, Moghimi SM, Pagliaro L, Park JH, Peer D, Ruoslahti E, Serkova NJ, Simberg D. Mechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutions. *ACS Nano* 2017;11:12-8.
- Gabizon AA, Patil Y, **La-Beck NM**. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. *Drug Resist Updat* 2016;29:90-106.
- Le AD, Alzghari SK, Jean GW, **La-Beck NM**. Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context. *Ther Clin Risk Manag* 2017;13:223-36.
- Walko CM, Aubert RE, **La-Beck NM**, Clore G, Herrera V, Kourlas H, Epstein RS, McLeod HL. Pharmacoepidemiology of clinically relevant hypothyroidism and hypertension from sunitinib and sorafenib. *Oncologist* 2017;22:208-12.
- **Lee CS**, Thomas CM, Ng KE. An overview of the changing landscape of treatment for advanced melanoma. *Pharmacotherapy* 2017 Jan 4.
- **Nedved AN**, DeFrates SR, Hladnik LM, Stockerl-Goldstein KE. Effect of linezolid on hematologic recovery in newly diagnosed acute myeloid leukemia patients following induction chemotherapy. *Pharmacotherapy* 2016;36:1087-94.
- Yang YT, Nagai S, Chen BK, Qureshi ZP, Lebby AA, Kessler S, Georgantopoulos P, Raisch DW, Sartor O, Hermanson T, Kane RC, Hrushesky WJ, Riente JJ, **Norris LB**, Bobolts LR, Armitage JO, Bennett CL. Generic oncology drugs: are they all safe? *Lancet Oncol* 2016;17:e493-e501.
- **Okumura LM**, Baruel Okumura PC, Veroneze C. Administration of all-trans retinoic acid through enteral tubes in acute promyelocytic leukemia: the handling of cytotoxic agents and clinical benefits. *Braz J Hematol Hemother* 2017;39:86-8.
- **Okumura LM**, D'Athayde Rodrigues F, Ferreira MA, Moreira LB. Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta-analyses of randomized controlled trials. *Br J Clin Pharmacol* 2016 Nov 20. [Epub ahead of print]
- **Okumura LM**, Silva DM, Comarella L. Relation between safe use of medicines and clinical pharmacy services at pediatric intensive care units. *Rev Paul Pediatr* 2016;34:397-402. English, Portuguese.
- Baruel Okumura PC, **Okumura LM**, Reis WC, Godoy RR, Cata-Preta BO, de Souza TT, Fávero ML, Correr CJ. Comparing medication adherence tools scores and number of controlled diseases among low literacy patients discharged from a Brazilian cardiology ward. *Int J Clin Pharm* 2016;38:1362-6.
- Cohn AL, Day BM, Abhyankar S, McKenna E, **Riehl T**, Puzanov I. BRAFV600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study. *Onco Targets Ther* 2017 Feb 17;10:965-71.
- **Smith JA**. White paper on natural products. *Pharmacotherapy* 2017;37:e1-e15.
- **Soefje S**. Pharmacists: integral to the management of chemotherapy-induced nausea and vomiting. *J Clin Oncol* 2016;34:3352-3.
- **Solimando D**. Lenalidomide, bortezomib, and dexamethasone (RVD) regimen for multiple myeloma. *Hosp Pharm* 2017;52:27-32.
- Chen CC, Parikh K, Abouzaid S, Purnomo L, McGuinness CB, Hussein M, **Wade RL**. Real-world treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or carfilzomib. *J Manag Care Spec Pharm* 2017;23:236-46.
- **Walko C**. Quantitation of targetable somatic mutations among patients evaluated by a personalized medicine clinical service: considerations for off-label drug use. *Pharmacotherapy* 2017 Feb 24 [Epub ahead of print]
- **Walko C**. Novel and expanded oncology drug approvals of 2016—PART 2: new options in the management of hematologic malignancies. *Oncology (Williston Park)* 2017;31.
- **Walko C**. Novel and expanded oncology drug approvals of 2016—PART 1: new options in solid tumor management. *Oncology (Williston Park)* 2017;31.
- **Walko C**. Key Lessons learned from Moffitt's Molecular Tumor Board: the Clinical Genomics Action Committee experience. *Oncologist* 2017;2:144-51.
- **Walko C**. Pharmacoepidemiology of clinically relevant hypothyroidism and hypertension from sunitinib and sorafenib. *Oncologist* 2017;2:208-12.

- **Walko C.** Precision medicine in oncology: new practice models and roles for oncology pharmacists. *Am J Health Syst Pharm* 2016;73:1935-42.
- **Walko C.** Pharmacogenomics, pharmacokinetics, and pharmacodynamics in the era of targeted therapies. *Am Soc Clin Oncol Educ Book* 2016;35:e175-84.
- **Williams C.** Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy. *Curr Opin Oncol* 2016;28:461-8.
- **Williams C.** Dual blockade of HER-2 provides a greater magnitude of benefit in patients with hormone-negative versus hormone-positive breast cancer. *Clin Breast Cancer* 2016;16:444-55.
- **Yee G.** Evaluation of community pharmacist ability to ensure the safe use of oral anticancer agents: a nationwide survey in Japan. *Jpn J Clin Oncol* 2017:1-9. [Epub ahead of print]

Other Notable Achievements

- **Larry Buie and LeAnn Norris:** HOPA Board At-Large Directors.

New ACCP Fellows

- **LeAnn Norris**

Interviews

- **Martino M.** New drug combo can treat STS. Interview with Joseph Ladd. *Pharmacy Today* 2016;22:32.
- **Smith JA, Stevich-Heemer B.** New drug. A novel drug, complete with diagnostics, approved for advanced ovarian cancer. Interview with Joseph Ladd. *Pharmacy Today* 2017;23:3.

Poster Presentations

- Xu F, Siu C, Barada F, **Martino M.** Evaluation of workflow within outpatient oncology infusion pharmacies at a large academic medical center using LEAN methodology. Presented at: Northwestern Memorial Hospital, Department of Pharmacy; Chicago, IL.

HIV PRN

The HIV PRN brings together almost 300 members and trainees with a dedicated interest in providing services to individuals living with HIV. PRN members are encouraged to share their diverse clinical practices, complex cases, research, education, and training experiences as they network with other members as well as seek clinical advice.

The PRN had a successful 2016 ACCP Annual Meeting in Hollywood, Florida. Our focus session on HIV in Special Populations was well attended; and the following business and networking meeting was a great opportunity to share ideas among the membership. In addition, the paper that the PRN membership worked on regarding acute care management of HIV-infected patients was recently published in *Pharmacotherapy* (March 2017)!

Additional notable achievements are as follows.

Awards

- **Milena McLaughlin:** Shining Star Award, Illinois Society of Health-System Pharmacists.
- **Kim K. Scarsi:** New Investigator Award, University of Nebraska Medical Center.

Publications

- **Durham SH, Badowski ME, Liedtke MD, Rathbun RC, Pecora Fulco P.** Acute care management of the HIV-infected patient: a report from the HIV Practice and Research Network of the American College of Clinical Pharmacy. *Pharmacotherapy* 2017 Mar. [Epub ahead of print]
- **Gordon LA,** Kumar P, Brooks KM, Kellogg A, McManus M, Alfaro RM, Nghiem K, George JM, Natarajan V, Lozier J, Penzak SR, Hadigan C. Antiretroviral boosting agent cobicistat increases the pharmacokinetic exposure and anticoagulant effect of dabigatran in HIV-negative healthy volunteers. *Circulation* 2016;134:1909-11.
- Bidell MR, **McLaughlin M,** Faragon J, Morse C, Patel N. Desirable characteristics of hepatitis C treatment regimens: a review of what we have and what we need. *Infect Dis Ther* 2016;5:299-312.
- Hawkins C, Grant J, Ammerman LR, Palella F, **McLaughlin M,** Green R, McGregor D, Stosor V. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective. *J Antimicrob Chemother* 2016;71:2642-5.
- **Scarsi KK,** Darin KM, Chappell CA, Nitz SM, Lamorde M. Drug-drug interactions, effectiveness, and safety of hormonal contraceptives in women living with HIV. *Drug Saf* 2016;39:1053-72.
- Neary M, Lamorde M, Olagunju A, Darin KM, Merry C, Byakika-Kibwika P, Back DJ, Siccardi M, Owen A, **Scarsi KK.** The effect of gene variants on levonorgestrel pharmacokinetics when combined with antiretroviral therapy containing efavirenz or nevirapine. *Clin Pharmacol Ther* 2017 Feb [Epub ahead of print]

Other Notable Achievements

- **Lori A. Gordon:** President, Southeastern Louisiana Society of Health-System Pharmacists.
- **Robert C. Macky:** Expanded collaborative practice agreement within the Mid-Atlantic Region of the Bureau of Prisons.

Immunology/Transplantation PRN

Awards

- **Ian Doyle:** Fellow, Oregon Society of Health-System Pharmacists (FOSHP), November 2016.
- **Christin Rogers:** ASHP Foundation Expansion Grant for Solid Organ Transplant PGY2 Program.

Publications

- Dember LM, Imrey PB, Duess MA, et al.; Hemodialysis Fistula Maturation Study Group; Feldman H, Farber A, Kaufman J, Stern L, LeSage P, Kivork C, Soares D, Malikova M, Allon M, Young C, Taylor M, Woodard L, Mangadi K, Munda R, Lee T, **Alloway R**, et al. Vascular function at baseline in the hemodialysis fistula maturation study. *J Am Heart Assoc* 2016;5(7).
- O'Connell PJ, Kuypers D, Mannon RR, Abecassis M, Chadban S, Gill JS, Murphy B, Nickerson PW, Schold JD, Stock P, Seron D, **Alloway R**, Bromberg J, Budde K, Jordan S, Legendre C, Lefaucheur C, Sarwall M, Segev D, Stegall MD, Tullius SG, Wong G, Woodle ES, Ascher N, Morris RE. Clinical trials for immunosuppression in transplantation; the case for reform and change in direction. *Transplantation* 2017 Feb 15. [Epub ahead of print]
- Dedhia P, Govil A, Mogilishetty G, **Alloway RR**, Woodle ES, Abu Jawdeh BG. Eculizumab and belatacept for de novo atypical hemolytic uremic syndrome associated with CFHR3-CFHR1 deletion in a kidney transplant recipient: a case report. *Transplant Proc* 2017;49:188-92.
- **Casale JP, Doligalski CT.** Pharmacologic considerations for solid organ transplant recipients who become pregnant. *Pharmacotherapy* 2016;36:971-82.
- **Covert K, Fleming JN, Casale JP**, Boyle KM, **Pilch NA, Meadows HB**, Mardis CR, McGillicuddy JW, Nadig S, Bratton CF, Chavin KD, Baliga PK, Taber DJ. Predicting and preventing readmissions in kidney transplant recipients. *Clin Transplant* 2016;30:779-86.
- **Covert K**, Mardis C, **Fleming J**, Pilch N, et al. Development of a predictive model for

drug-related problems in kidney transplant recipients. *Pharmacotherapy* 2017;37:159-69.

- Sebaaly JC, **Fleming J, Pilch N, Meadows H**, Finn A, Chavin K, Baliga P, Bratton CF, McGillicuddy JW, Nadig S, **Taber D**. Depression, resource utilization, and outcomes following liver transplant. *Prog Transplant* 2016.
- **Fleming JN, Taber DJ**, McElligott J, McGillicuddy JW, Treiber F. Health in solid organ transplant: the time is now. *Am J Transplant* 2017. Accepted for publication.
- **Fleming JN, Taber DJ, Pilch NA**, McGillicuddy JW, Srinivas TR, Baliga PK, Chavin KD, Bratton CF. A randomized, prospective comparison of transition to sirolimus-based CNI minimization or withdrawal in African American kidney transplant recipients. *Clin Transplant* 2016.
- **Fleming JN, Taber DJ, Pilch NA**, Srinivas TR, Chavin KD. Yes, we do still need IL-2 receptor antagonists [peer-reviewed letter to the editor]. *Am J Transplant* 2016.
- **Taber DJ, Fleming JN**, Fominaya CE, Gebregziabher M, Hunt KJ, Srinivas TR, Baliga PK, McGillicuddy JW, Egede LE. The impact of health care appointment non-adherence on graft outcomes in kidney transplantation. *Am J Nephrol* 2017;45:91-8.
- Jordan CL, **Taber DJ**, Kyle M, Connelly J, **Pilch N, Fleming J, Meadows HB**, Bratton CF, Nadig SN, McGillicuddy JW, Chavin KD, Baliga PK, Shatat IF, Twombly K. Incidence, risk factors, and outcomes of opportunistic infections in pediatric renal transplant recipients. *Pediatr Transplant* 2016;20:44-8.
- **Tremblay S**, Nigro V, Weinberg J, Woodle ES, **Alloway RR**. A steady-state head-to-head pharmacokinetic comparison of all FK-506 (tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, two arm, three period crossover study. *Am J Transplant* 2017;17:432-42.
- Paterno F, Girnita A, Brailey P, Witte D, Wang J, Cuffy MC, Diwan T, **Tremblay S**, Revollo JY, **Alloway RR**, Schoech MR, Anwar N, Shah SA, Woodle SE. Successful simultaneous liver-kidney transplantation in the presence of multiple high-titered class I and II antidonor HLA antibodies. *Transplant Direct* 2016;2:e121.
- **Trofe-Clark J**, Sawinski D. BK and other polyomaviruses in kidney transplantation. *Semin Nephrol* 2016;36:372-85.
- Higdon LE, **Trofe-Clark J**, Liu S, Margulies KB, Sahoo MK, Blumberg E, Pinsky BA, Maltzman JS.

Cytomegalovirus responsive CD8+ T cells expand after solid organ transplantation in the absence of CMV disease. *Am J Transplant* 2017 Feb 15. [Epub ahead of print]

- Koyawala N, Silber JH, Rosenbaum PR, Wang W, Hill AS, Reiter JG, Niknam BA, Even-Shoshan O, Bloom RD, Sawinski D, Nazarian S, **Trofe-Clark J**, Lim MA, Schold J, Reese PP. Comparing outcomes between antibody induction therapies in kidney transplantation. *J Am Soc Nephrol*. Accepted for publication.
- Reese PP, Bloom RD, **Trofe-Clark J**, Mussell A, Leidy D, Levsky S, Zhu J, Lin Y, Wang W, Troxel A, Feldmen HI, Volpp K. Automated reminders and physician notification to promote immunosuppression adherence among kidney transplant recipients: a randomized trial. *Am J Kidney Dis* 2016 Dec 7. [Epub ahead of print]

Poster Presentations

- **Covert KL**, Mardis CR, **Fleming JN**, **Pilch NA**, **Meadows HB**, Mardis BA, Mohan P, Posadas-Salas M, Srinivas T, **Taber DJ**. Development of a predictive model for drug-related problems in kidney transplant recipients. Poster presented at: American College of Clinical Pharmacy Annual Meeting; October 2016; Hollywood, FL.
- O'Brien B, Mardis C, Mardis A, **Fleming J**, **Meadows H**, **Patel N**, **Pilch N**, **Perez C**, Sell M, Rogers A, Lee I, McGillicuddy J, Chavin K, Dubay D, **Taber D**. Readmissions after liver transplantation—they may be predictable, but are they inevitable? American Transplant Congress; May 2017; Chicago, IL.
- **Fleming JN**, Lai JC, Te H, Said A, Spengler EK, Rogal SS. Opioid and opioid substitution therapy in liver transplant candidates: a survey of center policies and practices. American Transplant Congress; May 2017; Chicago, IL.
- **Moorman AF**, **Hurtik ML**, Pekarek A, Laskar S, Gupta D. Markers of coagulation and hemostasis activation in left ventricular assist device recipients. International Society of Heart and Lung Transplantation 37th Annual Meeting; April 2017; San Diego, CA.
- Rogers A, **Patel N**, **Fleming J**, Mardis C, Mardis A, **Meadows H**, **Pilch N**, **Perez C**, Sell M, O'Brien B, Lee I, McGillicuddy J, Chavin K, Dubay D, **Taber D**. Diabetes in liver transplantation: evaluation of the management and associated clinical outcomes. American Transplant Congress; May 2017; Chicago, IL.

- **Perez C**, **Fleming JN**, Mardis C, Mardis A, **Patel N**, **Meadows H**, **Pilch N**, Chavin K, Dubay D, **Roach K**, Triemer H, **Hurtik M**, Mehta A. Impact of timeliness of assessment of positive cytomegalovirus polymerase chain reaction results in abdominal organ transplant recipients. American Transplant Congress; May 2017; Chicago, IL.
- **Perez C**, **Fleming JN**, Mardis C, Mardis A, **Patel N**, **Meadows H**, **Pilch N**, Chavin K, Dubay D, Vinayak R, **Taber DJ**. Evaluation of renal function after a transition to everolimus or mycophenolate mofetil in liver transplant recipients. American Transplant Congress; May 2017; Chicago, IL.
- **Strout S**, **Pilch NA**, **Fleming JN**, et al. Do morbidly obese patients have an increased risk of infection post-kidney transplant? Presented at: American College of Clinical Pharmacy Annual Meeting; October 2016; Hollywood, FL.
- **Taber DJ**. This is why we can't have nice things—real world experience with everolimus in livers. American Transplant Congress; May 2017; Chicago, IL.
- **Trofe-Clark J**, Gbemudu W, Ryan S, Sawinski D, Lim M, Goral S, Bleicher M, Bloom RD, Reese PP. Assessments of literacy, cognitive function and transplant medication knowledge in renal transplant recipients. Accepted as poster at: American Transplant Congress; May 2017; Chicago, IL.
- Park J, **Trofe-Clark J**, Kaiser T, **Pilch N**, **Taber D**. Associations between provision of transplant pharmacy services and center-level patient and graft outcomes in U.S. adult kidney transplant programs. Accepted as poster at: American Transplant Congress Meeting; May 2017; Chicago, IL.

Oral Presentations

- **Alloway R**. Workshop on patient-focused drug development in transplantation. U.S. Food and Drug Administration, Department of Health and Human Services, CDER/Division of Special Pathogen and Transplant Products (Organizing Committee and Speaker); September 27, 2016.
- **Fleming JN**. Pharmacology of opioids: drug interactions and screening methods. American Transplant Congress; May 2017; Chicago, IL.
- **Fleming JN**, Jonassaint N, Satoskar R, Shapiro S, Dubay D, Chavin KD. LIVE-C free (LIVER transplant for hepatitis C: recurrence FREE). AHPBA; March 2017; Miami Beach, FL.
- **Fleming JN**, **Perez C**, **Sobhanian M**, **Taber DJ**, Chedister G, Axelrod DA, Chavin KD. Share35: increasing biliary complications and healthcare

resources? American Transplant Congress; May 2017; Chicago, IL.

- Sell M, **Meadows H**, Mardis A, Lee I, O'Brien B, **Perez C**, Rogers A, Mardis C, **Patel N**, **Fleming JN**, **Pilch NA**, Chavin K, **Taber DJ**. Cardiovascular events area substantial and increasing cause of graft loss in liver transplant recipients. American Transplant Congress; May 2017; Chicago, IL.
- **Roach K**, **Meredith E**, Lyon M. Impact of ritonavir on graft function in human immunodeficiency virus infected kidney transplant recipients. American Transplant Congress; May 2017; Chicago, IL.
- **Thielke J**. Updates in anti-viral therapy session: Featured Allied Health Symposium III. American Transplant Congress; May 2017; Chicago, IL.
- **Trofe-Clark J**. Invited speaker to present on immunosuppression in pregnancy and breast-feeding. Pregnancy after Transplantation: Research and Practicalities Symposium, Transplant Pregnancy Registry International - Gift of Life Institute; October 2016; Philadelphia, PA.
- **Trofe-Clark J**. Identification and management of high pharmacologic risk candidates. Invited faculty member to present at: Optimizing Pharmacologic Risk Assessment of Transplant Recipients and Living Donors Sunrise Symposium, Annual Meeting of the American Transplant Congress; May 2017; Chicago, IL.
- **Trofe-Clark J**, Gbemudu W, Truong J, Ryan S, Houston M, Shaffer J, Angerstein J, Barton N, Bleicher M, Goral S, Lim MA, Sawinski DA, Bloom RD, Reese PR. Pilot study results: cognitive function, health literacy, transplant-related medication knowledge base assessments early post-renal transplant. Accepted as oral presentation at: 2017 Transplant Nursing Symposium; June 2017; Lake Buena Vista, FL.
- Goldberg DS, Blumberg EA, Reddy R, Nazarian SM, Van Deerlin V, **Trofe-Clark J**, Levine M, Sawinski D, Bloom R, Abt P, Reese P. Transplanting hepatitis C kidneys into negative kidney recipients [THINKER] trial. Accepted as Plenary Session to: American Transplant Congress; May 2017; Chicago, IL.

Promotions

- **Kelly Covert**: Assistant Professor, Pharmacy Practice, East Tennessee State University Bill Gatton College of Pharmacy.
- **Jim Thielke**: Director, Pharmaceutical and Clinical Services, H.H.I.O.

Infectious Diseases PRN

The ID PRN is one of the largest PRNs, with just more than 2400 members, over one-third of whom are residents and students. The ID PRN has benefited greatly from the contributions of elected resident officers. This year, Krutika Mediwala and Seth Edwards serve in these positions as liaisons to several committees and as valued members of the Executive Committee. Moreover, the ID PRN has created two new committees (Social Media and Research) this year in addition to its four longstanding and active committees (Programming, Nominations, Awards, and Publications). The Social Media Committee has had great success since its formation. The committee has continually increased the ID PRN Twitter presence (@accpindprn, #IDPRN) to over 1100 followers and provided educational opportunities through which PRN members share ideas. In addition, the Social Media Committee has created an ID PRN Facebook page (<https://www.facebook.com/ACCP-Infectious-Diseases-PRN-581204852070088/>). The Research Committee is just getting started, but committee members look forward to collaborating with the ACCP PBRN and opportunities to further involve the membership with research opportunities. The Programming Committee has already been planning the 2017 ACCP Annual Meeting, and we look forward to finalizing excellent topics and speakers. Watch for information from the Nominations and Awards committees in the coming months regarding our PRN elected offices and opportunities for awards. Finally, watch for a newsletter from the Publications Committee soon.

Promotions

- **Jessica Cottreau**: Chair, Department of Pharmacy Practice, Rosalind Franklin University of Medicine and Science.
- **Chris Frei**: Appointee, Task Force on Infectious Diseases Preparedness and Response for Greg Abbott, Governor of Texas.

Awards

- **Sarah Blackwell**: 2016 New Practitioner of the Year, Alabama Society of Health-System Pharmacists.
- **Elias Chahine**: Forerunner Award, 2016 Florida Society of Health-System Pharmacists.
- **Tiffany Dickey**: First Place, Best Poster Award, and First Runner-up Poster Award, 2016 American College of Clinical Pharmacy Adult Medicine PRN.

Khalid Elijaaly:

- 2016 IDWeek Trainee Travel Award.
- Inaugural Jonathan Freeman Travel Scholarship from SHEA.

- **Chris Frei:** Top 10 Faculty and Mentor of the Year Awards (Pharmacotherapy Division), University of Texas at Austin College of Pharmacy.
- **Wesley Kufel:** 2016 American College of Clinical Pharmacy and the 2016 Triangle College of Clinical Pharmacy Resident/Fellow Travel Awards.
- **Milena McLaughlin:** Shining Star Award, Illinois Society of Health-System Pharmacists.

Krutika Mediwala:

- 2016 IDWeek Mentorship Travel Grant.
- 2016 American College of Clinical Pharmacy ID PRN Distinguished Research Trainee Award.

Publications

- Heo ST, **Aitken SL**, **Tverdek FP**, Kontoyiannis DP. How common is subsequent central nervous system toxicity in asymptomatic patients with haematologic malignancy and suprathreshold voriconazole serum levels? *Clin Microbiol Infect* 2017 Jan 7. [Epub ahead of print]
- Mojica MF, Ouellette CP, Leber A, Becknell MB, Ardura MI, Perez F, Shimamura M, Bonomo RA, **Aitken SL**, Shelburne SA. Successful treatment of bloodstream infection due to metallo- β -lactamase-producing *Stenotrophomonas maltophilia* in a renal transplant patient. *Antimicrob Agents Chemother* 2016;60:5130-4.
- **Al-Shaer M**, **Mansour H**, Elena H, Salameh H, Iqbal F. Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. *BMC Infect Dis* 2017;17:118.
- **Babic JT**, **Sofjan A**, **Babin M**, **Echevarria K**, **Ikwuagwu JO**, **Lam WM**, **Aitken SL**, **Perez KK**. Significant publications on infectious diseases pharmacotherapy in 2015. *Am J Health Syst Pharm* 2017;74:238-52.
- **Barber KE**, Bell AM, **King ST**, Parham JJ, **Stover KR**. Impact of piperacillin-tazobactam shortage on antimicrobial stewardship: implications for antimicrobial stewardship programs. *Braz J Infect Dis* 2016 Sep 5. [Epub ahead of print]
- **Barber KE**, Bell AM, **Stover KR**, **Wagner JL**. Intravenous vancomycin dosing in the elderly: a focus on clinical issues and practical applications. *Drugs Aging* 2016;33:845-54.
- Cretella DA, **Barber KE**, **King ST**, **Stover KR**. Comparison of susceptibility patterns using commercially available susceptibility testing methods performed on prevalent *Candida* species. *J Med Microbiol* 2016 Nov 1. [Epub ahead of print]
- Liu P, Ohl C, Johnson J, Williamson J, **Beardsley J**, Luther V. Frequency of empiric antibiotic de-escalation in an acute care hospital with an established antimicrobial stewardship program. *BMC Infect Dis* 2016;16:751-7.
- **Chahine EB**, **Sucher AJ**, **Hemstreet BA**. Sofosbuvir/velpatasvir: the first pan-genotypic direct-acting antiviral combination for hepatitis C. *Ann Pharmacother* 2017;51:44-53.
- **Chastain DB**, **Stover KR**, **King ST**. Infectious and non-infectious etiologies of cardiovascular disease in human immunodeficiency virus infection. *Open AIDS J* 2016;10:113-26.
- Warmack TS, **Dickey TA**. Vector-borne disease. Book 3. *Infection Primary Care, Ambulatory Care Self-Assessment Program (ACSAP)*, 1st ed. Lenexa, KS: American College of Clinical Pharmacy, 2016. In press.
- **Dilworth TJ**. Comment on: Importance of selection and duration of antibiotic regimen in prosthetic joint infections treated with debridement and implant retention. *J Antimicrob Chemother* 2016;71:3626-27.
- Bui C, Zhu E, **Donnelley MA**, Wilson MD, Morita M, Cohen SH, Brown J. Antimicrobial stewardship programs that target only high-cost, broad-spectrum antimicrobials miss opportunities to reduce *Clostridium difficile* infections. *Am J Infect Control* 2016;44:1684-6.
- **Frei CR**, Rehani S, Lee GC, Boyd NK, Attia E, Pechal A, Britt RS, Mortensen EM. Application of a risk score to identify older adults with community-onset pneumonia most likely to benefit from empiric *Pseudomonas* therapy. *Pharmacotherapy* 2017;37:195-203.
- Attridge RT, **Frei CR**, Pugh MJ, Lawson KA, Ryan L, Anzueto A, Metersky ML, Restrepo MI, Mortensen EM. Health care-associated pneumonia in the intensive care unit: guideline-concordant antibiotics and outcomes. *J Crit Care* 2016.
- Lee GC, Hall RG, Boyd NK, Dallas SD, Du LC, Trevino LB, Retzliff C, Trevino SB, Lawson KA, Wilson JP, Olsen RJ, Wang Y, **Frei CR**. Predictors of community-associated *Staphylococcus aureus*, methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* skin and soft tissue infections in primary-care settings. *Epidemiol Infect* 2016:1-7.
- Lee GC, Hall RG, Boyd NK, Dallas SD, Du LC, Trevino LB, Trevino SB, Retzliff C, Lawson KA, Wilson J, Olsen RJ, Wang Y, **Frei CR**. A prospective observational cohort study in primary care practices to identify factors associated with

treatment failure in *Staphylococcus aureus* skin and soft tissue infections. *Ann Clin Microbiol Antimicrob* 2016;15:58.

- **Gauthier T**, Moreira E, Chan C, Cabrera A, Toro M, Carrasquillo MZ, Coentini M, Sherman EM. Pharmacist engagement within a hepatitis C ambulatory care clinic in the era of a treatment revolution. *J Am Pharm Assoc* 2016;56:670-6.
- **Giancola SE, Mahoney MV**, Hogan MD, Raux BR, **McCoy C, Hirsch EB**. Assessment of fosfomycin for complicated or multidrug-resistant urinary tract infections: patient characteristics and outcomes. *Chemotherapy* 2017;62:100-4.
- Walker E, Lyman A, **Gupta K, Mahoney MV**, Snyder GM, Hirsch EB. Clinical management of an increasing threat: outpatient urinary tract infections due to multidrug-resistant uropathogens. *Clin Infect Dis* 2016;63:960-5.
- **Hirsch EB, Mahoney MV**, Snyder GM, Gupta AK. Reply to Johnson. *Clin Infect Dis* 2017;64:529-30.
- **Jones BM, Bland CM**. Penicillin skin testing as an antimicrobial stewardship initiative. *Am J Health Syst Pharm* 2017;74:232-7.
- **Kufel WD**, Scrimenti A, Steele JM. A case of septic shock due to *Serratia marcescens* pyelonephritis and bacteremia in a patient receiving empagliflozin. *J Pharm Pract* 2016. [Epub ahead of print]
- Lasalvia MT, Branch-Elliman W, Snyder GM, **Mahoney MV**, Alonso CD, Gold HS, Wright SB. Does tigecycline improve outcomes in severe-complicated, nonoperative *Clostridium difficile* infection? *Open Forum Infect Dis* 2017;4(1).
- Chamoun NR, Zeenny R, **Mansour H**. Impact of clinical pharmacy interventions on medications error nodes. *Int J Clin Pharm* 2016;38:1436-44.
- Jamhour A, El-Kheir A, Salameh P, Abi Hanna P, **Mansour H**. Antibiotic knowledge and self-medication practices in a developing country: a cross-sectional study. *Am J Infect Control* 2017 Jan 11.
- **Martin MT**. Gastrointestinal disorders. In: Bainbridge JL, Cardone K, Cross LB, et al., eds. *Updates in Therapeutics®: Ambulatory Care Pharmacy Preparatory Review and Recertification Course*, 2017 ed. Lenexa, KS: American College of Clinical Pharmacy, 2017:597-708.
- **Martin MT**, Faber DM. Patient satisfaction with the clinical pharmacist and prescribers during hepatitis C virus management. *J Clin Pharm Ther* 2016;41:645-9.
- Bidell MR, **McLaughlin M**, Faragon J, Morse C, Patel N. Desirable characteristics of hepatitis C treatment regimens: a review of what we have and what we need. *Infect Dis Ther* 2016;5:299-312.
- Hawkins C, Grant J, Ammerman LR, Palella F, **McLaughlin M**, Green R, McGregor D, Stosor V. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective. *J Antimicrob Chemother* 2016;71:2642-5.
- **McLaughlin MM**, Masic I, Gerzenshtein L. Evaluation of nucleoside reverse transcriptase inhibitor dosing during continuous veno-venous hemofiltration. *Int J Clin Pharm* 2017;39:37-40.
- **Okumura LM**, et al. Meropenem-induced low valproate levels in a cerebral palsy child. *Braz J Infect Dis*. [Epub ahead of print]
- **Okumura LM**, Riveros BS, Gomes MM, Veroneze I. Strategies of hospital antimicrobial stewardship associated with different health outcomes. *Lancet Infect Dis* 2016;16:999-1000.
- **Okumura LM**, Veroneze I, Burgardt CI, Frago MF. Effects of a computerized provider order entry and a clinical decision support system to improve cefazolin use in surgical prophylaxis: a cost saving analysis. *Pharm Pract* 2016;14:717.
- **Phe K, Shields RK, Tverdek FP, Aitken SL, Guervil DJ, Lam WM, Musgrove RJ, Luce AM, Tam VH**. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multi-centre, retrospective, cohort study. *J Antimicrob Chemother* 2016;71:3585-7.
- Arizpe A, **Reveles KR, Aitken SL**. Regional variation in antibiotic prescribing among medicare part D enrollees, 2013. *BMC Infect Dis* 2016;16:744.
- Arizpe A, **Reveles KR**, Patel SD, **Aitken SL**. Updates in the management of cephalosporin-resistant gram-negative bacteria. *Curr Infect Dis Rep* 2016;18:39.
- **Rhodes NJ, Wagner JL**, Gilbert EM, **Crew PE, Davis SL, Scheetz MH**. Days of therapy and antimicrobial days: similarities and differences between consumption metrics. *Infect Control Hosp Epidemiol* 2016;37:971-3.
- **Stover KR, Bland CM, Gallagher JC**. The point of antimicrobial susceptibility testing is to inform antimicrobial prescribing. *Clin Infect Dis* 2017;64:103-4.
- **Terriff CM, Costanigro LT**, McKeirnan KC, Hoehn BJ. Clinical management of potential bioterrorism related conditions. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. *Pharmacotherapy: A*

Pathophysiologic Approach, 10th ed. New York: McGraw-Hill, 2016.

- **Timbrook TT**, Hurst JM, **Bosso JA**. Impact of an antimicrobial stewardship program on antimicrobial utilization, bacterial susceptibilities, and financial expenditures at an academic medical center. *Hosp Pharm* 2016;51:703-11.
- **Timbrook TT**, **Morton JB**, McConeghy KW, Caffrey AR, Mylonakis E, LaPlante KL. The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review & meta-analysis. *Clin Infect Dis* 2016;64:15-23.
- Caffrey AR, **Timbrook TT**, Noh E, Sakoulas G, Opal SM, Nizet V, **LaPlante KL**. Evidence to support continuation of statin therapy in patients with *Staphylococcus aureus* bacteremia. *Antimicrob Agents Chemother* 2017 Jan 9. [Epub ahead of print]
- DiPippo AJ, **Tverdek FP**, Tarrand JJ, Munita JM, **Tran TT**, Arias CA, Shelburne SA, Aitken SL. Daptomycin non-susceptible *Enterococcus faecium* in leukemia patients: role of prior daptomycin exposure. *J Infect* 2017;74:243-7.
- **Veve MP**, **Wagner JL**, Kenney RM, Grunwald JL, **Davis SL**. Reduction of unnecessary carbapenem use: comparison of fosfomycin to ertapenem for extended-spectrum beta-lactamase urinary tract infections. *Int J Antimicrob Agents* 2016;48:56-60.
- **Wagner JL**, Bell AM. Acute hepatic injury with amphotericin B deoxycholate in an immunocompetent patient. *J Pharmacol Pharmacother* 2016;7:112-4.
- **Wagner JL**, Kenney RM, Vazquez JA, Ghanem TA, **Davis SL**. Surgical prophylaxis with gram-negative activity reduces surgical site infections after microvascular reconstruction for head and neck cancer. *Head Neck* 2016;38:1449-54.
- Bell AM, **Wagner JL**, **Barber KE**, **Stover KR**. Elbasvir/grazoprevir: the latest agent in the fight against hepatitis C. *Int J Hepatol* 2016;2016:3852126.
- **White BP**, **Barber KE**, **Stover KR**. Evidence for ceftaroline fosamil for *Staphylococcus aureus* bacteremia. *Am J Health Syst Pharm* 2017;74:201-8.
- Gentry CA, **Williams RJ II**. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with *Pseudomonas aeruginosa* bacteraemia treated with piperacillin/tazobactam. *Int J Antimicrob Agents* 2017 [Epub ahead of print]
- Ratliff AR, Gentry CA, **Williams RJ II**. A propensity score-matched analysis of the impact of minimum

inhibitory concentration on mortality in patients with *Pseudomonas aeruginosa* bacteremia treated with cefepime or ceftazidime. *Diagn Microbiol Infect Dis* 2017;87:376-81.

- **Zemles TN**. Summary of the American Academy of Pediatrics updated guidelines for palivizumab prophylaxis. *J Pharm Soc Wis* 2016;19:40-1.
- **Zemles TN**, Gaertner KM, Gutzeit MF, Willoughby RE. Implementation of American Academy of Pediatrics guidelines for palivizumab prophylaxis in a pediatric hospital. *Am J Health Syst Pharm* 2016;73:405-8.
- **Zemles TN**, Thompson NE, Havens PL, Kaufman BA, Huppler AR. An optimized voriconazole dosing strategy to achieve therapeutic serum concentrations in children younger than 2 years old. *Pharmacotherapy* 2016;36:1102-8.

Other Notable Achievements

- **Sarah Blackwell**: BCCCP certification.
- **Wesley Kufel**: AAHIVP and BCPS certification.
- **Krutika Mediwala, Lucas Okumura, and Jamie Wagner**: BCPS certification.
- **Tracy Zemles**: MAD-ID Advanced Antimicrobial Stewardship Training Program.

Nephrology PRN

The Nephrology PRN is actively improving its member benefits by increasing its presence on social media and the PRN website. We are also working on our focus session programming for the 2017 ACCP Annual Meeting. We recently elected two new representatives to the Kidney Health Initiative (KHI). KHI brings together industry, nephrologists, patients with kidney disease, pharmacists, government agencies, and other interested parties to improve research for our patients.

Publications

- **Dager WE**, Lee JA. Filtering out use of DOACs in hemodialysis. *Ann Pharmacother* 2017.
- **Ei Nekidy WS**, El-Masri MM, Umstead GS, Dehoorne-Smith M. Predicting maintenance doses of vancomycin for hospitalized patients undergoing hemodialysis. *Can J Hosp Pharm* 2016;69:341-7.
- **Maxson R**, Pate J, Starr J. Evaluation of weight-based vancomycin dosing for hospitalized hemodialysis patients. *Ren Fail* 2016;38:1677-82.
- **Nguyen T**, Cina A, Henriques S. The effects of concomitant use of PPIs on iron supplementations. *J Nurs Pract* 2017;13:e95-7.

- **Nguyen T**, Gelband K. A case-based approach to evaluate the potential risks associated with fluorquinolones and steroids. *Consult Pharm* 2016;31:646-9.
- **Nguyen T**, Li Y, Refua S. Gabapentin: a surprise drug with many uses. *J Pharm Pract Res* 2017.
- **Nguyen T**, Pham D, Huynh T. Phosphate binder choices used in ESRD patients. *Nephrology News & Issues* 2016 July:37-38.
- Pham AQ, Sexton J, Wimer D, Rana I, **Nguyen T**. Managing hyperkalemia: stepping into a new frontier. *J Pharm Pract* 2016 September

Other Notable Achievements

- **Wasim El Nekidy**: Outcomes of vancomycin guidelines recommended dosing in outpatients undergoing hemodialysis, a retrospective analysis. Poster to be presented at: 27th European Congress of Clinical Microbiology and Infectious Diseases; April 2017; Vienna, Austria.
- **Joanna Q. Hudson**: Will be on the spring 2017 ballot as a candidate for American College of Clinical Pharmacy Secretary, Board of Regents.
- **Melanie Joy** and **Amy Barton Pai**: Newly elected Nephrology PRC representatives to the Kidney Health Initiative.
- **Timothy Nguyen**: Honorary member of the Phi Lambda Sigma Pharmacy Leadership Society, Beta Kappa Chapter, in recognition of outstanding leadership and service to the pharmacy profession.
- **Wendy St. Peter** and **Harold Manley**: Developed a Medication Reconciliation Measure for Dialysis Patients through work with the Kidney Care Quality Alliance Measure Feasibility and Testing Workgroup. Endorsed by the National Quality Forum.

Pain and Palliative Care PRN

Promotions

- **Sandra DiScala**: Clinical Pharmacy Specialist, West Palm Beach VAMC.
- **Mary Lynn McPherson**: Executive Director, Advanced Post-Graduate Education in Palliative Care, University of Maryland School of Pharmacy.

Publications

- Tran NN, **DiScala SL**, Mandi D, Pavlides AC, Marks S, Silverman MA. Discontinuation of statins at the end of life #322. *J Palliat Med* 2017;20:199-200.

- **DiScala SL**, Onofrio S, Miller M, Nazario M, Silverman M. Integration of a clinical pharmacist into an interdisciplinary palliative care outpatient clinic. *Am J Hosp Palliat Med* 2016;1-6.
- **Essex MN**, Hopps M, Bienen EJ, Udall M, Mardekian J, Makinson GT. Evaluation of the relationship between serum uric acid levels and cardiovascular events in patients with gout: a retrospective analysis using electronic medical record data. *J Clin Rheum* 2017. [Epub ahead of print]
- Burke CA, Phillips R, Berger M, Li C, **Essex MN**, Iorga D, Lynch PM. Children's International Polyposis (CHIP) study: a randomised, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis. *J Clin Exper Gastroenterol*. Accepted for publication.
- Diaz-Borjon, E, Torres-Gomez A, **Essex MN**, Salomon P, Li C, Cheung R, Parsons B. Parecoxib provides analgesic and opioid-sparing effects following major orthopedic surgery: a subset analysis of a randomized, placebo-controlled clinical trial. *Pain Ther* 2017. [Epub ahead of print]
- Walker C, **Essex MN**, Li C, Park PW. Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: a 12-week randomized study in Norwegian patients. *J Int Med Res* 2016;44:483-95.
- **Noyes MN**. Investigator-initiated research. In: *Essentials of the Pharmaceutical Industry for Health Care Professionals*. Pfizer, 2016:20-3.
- **Pruskowski J**. Deprescribing #321. *J Palliat Med* 2017;20:197-8.
- **Pruskowski J**, Arnold R, Skledar SJ. Development of a health-system palliative care clinical pharmacist. *Am J Health Syst Pharm* 2017;74:e6-e8.
- **Pruskowski J**, Arnold RM. Opioid pharmacokinetics #307. *J Palliat Med* 2016;19:668-70.
- Campbell R, Tycon L, **Pruskowski J**. Corticosteroid-induced psychiatric symptoms #323. *J Palliat Med* 2017;20:298-9.
- Felton M, Weinberg R, **Pruskowski J**. Olanzapine for nausea, delirium, anxiety, insomnia, and cachexia #315. *J Palliat Med* 2016;19:1224-5.

Presentations

- **Essex MN**, Cheung R, Li C. The effects of parecoxib on movement-related pain following major gynecological surgery. Presented at: Euroanaesthesia 2016; May 2016; London, UK. Published in: *Eur J Anaesthesiol* 2016;33:e-Supplement 54.
- **Essex MN**, Cheung R, Li C, Xie L. Safety of greater than 3 days of therapy with parecoxib injection in

the management of postoperative pain. Presented at: American College of Clinical Pharmacy Virtual Poster Symposium; May 2016.

- **Essex MN**, Schug S, Parsons B, Li C, Xia F, Cheung R. The safety profile of parecoxib for the treatment of post-operative pain: an examination of over 10 years of post-authorization safety data. Presented at: Euroanaesthesia 2016; May 2016; London, UK. Published in: *Eur J Anaesthesiol* 2016;33:e-Supplement 54.

Other Notable Achievements

- **Sandra DiScala**: Chair-Elect, Pharmacotherapy SIG, American Academy of Hospice and Palliative Medicine, February 2017.

Margaret Essex:

- NYU and Weill Cornell Pharmaceutical Medicine Elective Steering Committee member.
- Founding Member of the Steering Committee for the Pharmaceutical Medicine Medical School Clerkship, monthly lecturer and preceptor.
- **Mary Lynn McPherson**: Professor and Executive Director, Advanced Postgraduate Education in Palliative Care, Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy.
- **Jennifer Pruskowski**: Chair, Pharmacotherapy SIG, American Academy of Hospice and Palliative Medicine.
- **Richard Wheeler**: Member, Joint Commission Standards Review Panel focused on proposed standards revisions related to Pain Assessment and Pain Management.

Pediatrics PRN

Promotions

Kalen B. Manasco:

- Clinical Professor, University of Florida College of Pharmacy and UF Health Shands.
- Associate Chair, Department of Pharmacotherapy and Translational Research.

Awards

Allison Blackmer:

- Recognition as writing one of the top 10 articles from *Pharmacotherapy* in 2016.
- Innovations in Teaching Award, AACP, July 2016.

Publications

- **Blackmer AB**. Fluids, electrolytes, and nutrition. ACCP Updates in Therapeutics® 2017: Pediatric Pharmacy Preparatory Review and Recertification Course, 2017:1-1-1-36.
- **Blackmer AB**. Fluids, electrolytes, and nutrition. ACCP Updates in Therapeutics® 2016: Pediatric Pharmacy Preparatory Review and Recertification Course, 2016:1-199-1-233.
- **Blackmer AB**, Feinstein JA. Management of sleep disorders in children with neurodevelopmental disorders: a review. *Pharmacotherapy* 2016;36:84-98. Note: Recognized as one of the Top 10 papers in *Pharmacotherapy* in 2016.
- **Blackmer AB**, Konicek C, Baker N, Penzien C, Welch KB, Klein KC. Impact on student performance following implementation of a pediatric core curriculum during a generalist APPE: pilot data. *Curr Pharm Teach Learn* 2016;8:96-103.
- Chen CH, Harris MB, Partipilo ML, Welch KB, Teitelbaum DH, **Blackmer AB**. Impact of the nationwide intravenous selenium product shortage on the development of selenium deficiency in infants dependent on long-term parenteral nutrition. *JPEN J Parenter Enteral Nutr* 2016;40:851-9.
- Compher C, Dudrick SJ, Wesley JR, Malone A, Sacks GS, McMahon MM, Winkler MF, Morgensen KM, Kurkchubasche A, Arnold MA, Yang H, **Blackmer AB**, Braunschweig C, Han-Markey T, Partipilo ML, Harris MB, Kovacevich D, Peters B, Cantwell A, Fithian MA. Tributes to Daniel H. Teitelbaum, M.D., Ph.D. *JPEN J Parenter Enteral Nutr* 2016;40:1079-86.
- Dickerson RN, Kumpf VJ, **Blackmer AB**, Bingham AL, Tucker AM, Ybarra JV, et al. Significant published articles for pharmacy nutrition support practice in 2014 and 2015. *Hosp Pharm* 2016;41:539-52.
- Saseen JJ, **Blackmer AB**, Thompson M, Brunner J. Implementation of a novel intercession course during the P4 year. *Am J Pharm Educ* 2016;80:Article S2, p. 121. Winner of Innovations in Teaching Award (AACP). Poster presented at: AACP Annual Meeting; July 2016; Anaheim, CA.
- Smith IM, Corkum PV, **Blackmer AB**, Feinstein JA. Steps toward evidence-based management of sleep problems in children with neurodevelopmental disorders. *Pharmacotherapy* 2016;36:e80-2.
- Wu TT, **Hoff DS**. Accidental epidural injection of rocuronium in a pediatric patient: a case report and literature review. *J Pediatr Pharmacol Ther* 2016;21:436-43.

- Capino AC, Miller JL, **Johnson PN**. Clonidine for sedation and analgesia and withdrawal in critically ill infants and children. *Pharmacotherapy* 2016;12:1290-9.
- Duncan-Azadi CR, **Johnson PN**, Gormley AK. Midazolam withdrawal induced catatonia in a nine-year-old patient. *A A Case Rep* 2017 Feb 8.
- Hughes KM, **Johnson PN**, Anderson MP, Sekar KC, Welliver RC, Miller JL. Comparison of amikacin pharmacokinetics in neonates pre and post a dosing protocol change. *J Pediatr Pharmacol Ther* 2017;22:33-40.
- Ibach BW, **Johnson PN**, Ernst KD, Harrison D, Miller JL. Initial dosing and taper complexity of methadone and morphine for treatment of neonatal abstinence syndrome. *J Pharm Technol* 2016;32:216-22.
- Ibach BW, Miller JL, Woo S, Harrison D, Standifer K, Hagemann TM, **Johnson PN**. Characterization of tolerance in children during fentanyl continuous infusions. *J Pediatr Intensive Care* 2016;1-8.
- Van Tuyl JS, Jones AN, **Johnson PN**. Meropenem-induced neutropenia in a neonate. *J Pediatr Pharmacol Ther* 2016;21:353-7.
- Loudin S, Murray S, **Prunty L**, Davies T, Evans J, Werthammer J. An atypical withdrawal syndrome in neonates prenatally exposed to gabapentin and opioids. *J Pediatr* 2017;181:286-8.

Other Notable Achievements

- **Allison Blackmer**: BCPPS certification, December 2016.
- **Pete Johnson**: Fellow, Pediatric Pharmacy Advocacy Group, 2016.

Perioperative Care PRN

The Perioperative Care PRN celebrated its 2 years in existence at the 2016 ACCP Annual Meeting. Membership has rapidly grown to over 110 members! This PRN was established to provide education and resources related to the overall treatment of perioperative patients. Areas of interest range from regulatory requirements to early recovery after surgery to multimodal pain management and beyond.

The Perioperative Care PRN is actively working on the 2017 ACCP Annual Meeting focus session with an emphasis on enhanced recovery after surgery (ERAS) protocols and the pharmacist's role. Other 2016–2017 initiatives include increasing our web presence, increasing our membership, and developing a possible webinar series on perioperative topics and a white paper on

pharmacy perioperative care. We have been soliciting interest from Perioperative Care PRN members for participation in writing the white paper.

The Perioperative Care PRN is pleased to recognize the following members for their awards and accomplishments:

Awards

- **Richard H. Parrish II**: 2017 Distinguished Alumnus, Ohio State University College of Pharmacy.

Publications

- Silvestri H, **Birrer K**, Smith K, Brady J. 881: impact of an emergency department pharmacist on the management of acute ischemic stroke. *Crit Care Med* 2016;44:296.
- **Gaviola M**, McMilian WD, Ames SE, Alston WK. A retrospective study on the protective effects of topical vancomycin in patients undergoing multilevel spinal fusion. *Pharmacotherapy* 2016;36:19-25.
- Treto K, Safcsak K, **Giancarelli A**, Bhullar I. 1555: Obesity (BMI > 30) weighs heavily on outcome after penetrating trauma requiring immediate operation. *Crit Care Med* 2016;44:464.
- **Hobbs B**, **Giancarelli A**, Bhullar I. 1357: the effect of obesity on mortality in trauma patients with sepsis. *Crit Care Med* 2016;44:415.

New ACCP Fellows

- **Suzanne A. Nesbit**

Other Notable Achievements

Richard H. Parrish II:

- Invited expert, Ministry of Health Department of Pharmacy Services, Government of Singapore, Clinical Pharmacy Workload and Predictive Analytics Colloquium, 2017.
- Member, Board of Pharmacy Specialties, Inaugural Employer.

Pharmacokinetics/Pharmacodynamics/ Pharmacogenomics PRN

Awards

- **Mary Ensom**: 2016 Canadian Society of Hospital Pharmacists BC Branch Publication Award (Original Research Category).
- **Jason Karnes**: University of Florida Outstanding Young Alumnus.

- **Tony Kiang:** Canadian Society of Hospital Pharmacists (British Columbia branch) Primary Research Publication Award.

Grants

- **Jason Karnes:** American Heart Association Scientist Development Grant.

Publications

- **Caudle KE**, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE, Relling MV, Hoffman JM. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). *Genet Med* 2016 Jul 21.
- **Caudle KE, Gammal RS**, Whirl-Carrillo M, **Hoffman JM**, Relling MV, Klein TE. Evidence and resources to implement pharmacogenetic knowledge for precision medicine. *Am J Health Syst Pharm* 2016;73:1977-85.
- Bell GC, **Caudle KE**, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, Gaedigk A, Agundez JA, Sadhasivam S, Klein TE, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for *CYP2D6* genotype and use of ondansetron and tropisetron. *Clin Pharmacol Ther* 2016 Dec 21.
- Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, **Caudle KE**, Stingl JC. Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for *CYP2D6* and *CYP2C19* genotypes and dosing of tricyclic antidepressants: 2016 update. *Clin Pharmacol Ther* 2016 Dec 20.
- Hoffman JM, Dunnenberger HM, Hicks JK, **Caudle KE**, Whirl-Carrillo M, Freimuth RR, Williams MS, Klein TE, Peterson JF. Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC). *Am Med Inform Assoc* 2016;23:796-801.
- Johnson JA, **Caudle KE**, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, Cavallari LH, Wadelius M. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. *Clin Pharmacol Ther* 2017 Feb 15.

- Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agúndez JA, Wingard JR, McLeod HL, Klein TE, Cross S, **Caudle KE**, Walsh TJ. Clinical Pharmacogenetics Implementation Consortium (CPIC[®]) guideline for *CYP2C19* and voriconazole therapy. *Clin Pharmacol Ther* 2016 Dec 16.
- Pasternak AL, Crews KR, **Caudle KE**, Smith C, Pei D, Cheng C, Broeckel U, Gaur AH, Hankins J, Relling MV, Haidar CE. The impact of the *UGT1A1*60* allele on bilirubin serum concentrations. *Pharmacogenomics* 2017;18:5-16.
- Houlihan S, Decarie D, Benes C, Cleve R, Vidler M, Magee LA, **Ensom MHH**, von Dadelszen P. Magnocaine, a new take on an old drug for pre-eclampsia: physical compatibility and chemical stability of magnesium sulphate and lidocaine hydrochloride in pre-filled syringes. *J Obstet Gynaecol Can* 2016;38:926-44.
- LeBras M, Chow I, Mabasa VH, **Ensom MHH**. Systematic review of efficacy, pharmacokinetics, and administration of intraventricular aminoglycosides in adults. *Neurocrit Care* 2016;25:492-507.
- Ng JCY, Leung M, Wright AJ, **Ensom MHH**. Clinical pharmacokinetic monitoring of leflunomide in renal transplant recipients with BK virus reactivation—a review of the literature. *Clin Pharmacokinet*. [First Online: 28 February 2017]
- Peterson S, Lau TTY, **Ensom MHH**. Combination of ceftriaxone and ampicillin for the treatment of enterococcal endocarditis: a qualitative systematic review. *Ann Pharmacother* 2017 Feb 1. [Epub ahead of print]
- **Gammal RS**, Gardner KN, Burghardt KJ. Where to find guidance on using pharmacogenomics in psychiatric practice. *Curr Psychiatry* 2016;15:93-4.
- **Karnes JH**, Shaffer CM, Bastarache L, Gaudieri S, Glazer AM, Steiner H, Mosley JD, Mallal S, Denny JC, Phillips EJ, Roden DM. Comparison of allelic imputation programs. *PLoS One* 2017. In press.
- Aljabri A, Huckleberry Y, **Karnes JH**, Gharaibeh M, Kutbi S, Raz Y, Yun S, Abraham I, Erstad B. Cost-effectiveness of anticoagulants for the management of suspected heparin-induced thrombocytopenia in the United States. *Blood* 2016;128:3043-51.
- Mosley JD, Witte J, Larkin E, Bastarache L, Shaffer CM, **Karnes JH**, Stein CM, Phillips EJ, Hebrington S, Brilliant M, Mayer J, Ye Z, Roden DM, Denny JC. Identifying genetically driven clinical phenotypes using linear mixed models. *Nat Commun* 2016;7:11433.

- Cheng W, **Kiang TK**, Bring P, Ensom MH. Predictive performance of the Winter-Tozer and derivative equations for estimating free phenytoin concentration. *Can J Hosp Pharm* 2016;69:269-79.
- Job KM, **Kiang TK**, Constance JE, Sherwin CM, Enioutina EY. Herbal medicines: challenges in the modern world. Part 4. Canada and United States. *Expert Rev Clin Pharmacol* 2016;9:1597-609.
- **Kiang TKL**, Wilby KJ, **Ensom MHH**. Book: Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs. Cham, Switzerland: Springer.

Women's Health PRN

Publications

- **Bartelme KM**, Neiduski ML, Traynor AT, Lemoine N. An individualized approach to student progression at a school of pharmacy. *Curr Pharm Teach Learn* 2016;8:863-70. www.pharmacyteaching.com/article/S1877-1297%2815%2930172-6/pdf.
- **Borgelt LM**, Hart FM, Bainbridge JL. Epilepsy during pregnancy: focus on management strategies. *Int J Womens Health* 2016;8:505-17.
- Devries J, **Rafie S**, Polston G. Implementing an overdose education and naloxone distribution program in a health system. *J Am Pharm Assoc* 2017;57:S154-60.
- Rowshanrad S, Kneebusch J, **Rafie S**. Medical management of sexual assault survivors at an academic medical center. *JWRH* 2016;1.
- Schnock KO, Dykes PC, Albert J, Ariosto D, Call R, Cameron C, Carroll DL, Drucker A, Fang L, Garcia-Palm C, Husch M, Maddox RR, McDonald N, McGuire J, **Rafie S**, Robertson E, Saine D, Sawyer MD, Smith LP, Stinger KD, Vanderveen TW, Wade E, Yoon CS, Lipsitz S, Bates DW. The frequency of intravenous medication administration errors related to smart infusion pumps: a multi-hospital observational study. *BMJ Qual Saf* 2017;26:131-40.

Other Notable Achievements

- **Gerald Briggs**: Finished copyediting the 11th edition of *Drugs in Pregnancy and Lactation*, due in May.

Julie Kelsey:

- Invited to speak at the Clinical Pharmacy Conference in Austria on women's health topics—heart disease, depression, osteoporosis, and flibanserin.
- Spoke at the ASHP meeting on "PE in Pregnancy."

Sally Rafie:

- President, San Diego County Pharmacists Association.
- Member, Preconception Health Council of California.
- Advanced Practice Pharmacist license in California (new license as of February 2017).

Abigail (Abby) Yancey:


- ACCP Fellow.
- Faculty, St. Louis College of Pharmacy, St. Louis.

RESEARCH INSTITUTE UPDATE

ACCP Research Institute



We want to share a quick update on select programs, activities, and successes of the RI. We also invite you to visit our website (www.accpri.org) for updates and program announcements. Thank you for supporting the ACCP RI.



ACCP PBRN Interactive Series Posted Online with Testimonials

The ACCP The PBRN has released a three-part, interactive series, "Get to Know Your Network," to better acquaint ACCP members with the PBRN, its resources, and how clinicians and researchers can work with their colleagues on research studies within their own areas of clinical interest. This series addresses the basics of practice-based research, what the ACCP PBRN does, and how clinicians and researchers alike can become more involved in network collaborations.

The first two parts of this series, "The PBRN: A Research Resource" and "Collaborating with the ACCP Practice-Based Research Network (PBRN)," were delivered in September 2016 in an interactive webinar platform. The final part of the recorded series, "Testimonials from ACCP PBRN Participants," details the personal experiences of current members who have worked with the PBRN on various research activities. We invite you to enjoy the entire series on our website (www.accpri.org/pbrn/whyJoin.aspx).

How Do I Join the ACCP PBRN?

Joining the ACCP PBRN is free to all ACCP members. You can join the PBRN as an individual or as part of an existing network by completing our online registry at www.accpri.org/pbrn/registration.aspx. We invite you to browse our “Now Recruiting” and “Ongoing” studies by visiting our website (www.accpri.org/pbrn/researchProjects.aspx) or share your idea for a potential PBRN study at any time (www.accpri.org/pbrn/StudySuggest.aspx). You can also sign up to receive e-mail notifications about future studies.

Calling All Researchers!

The ACCP PBRN is interested in establishing collaborative research efforts with both ACCP PBRN and other external investigators. If you have a funded project or are applying for funding and are interested in collaborating with the ACCP PBRN, we invite you to complete our Project Concept Description Template at www.accpri.org/pbrn/partner.aspx. Please contact PBRN staff with any questions, or for assistance with developing a clinical question into a PBRN study, at (913) 492-3311 or pbrn@accp.com.

ACCP PBRN New Study Invitation: Clinical Pharmacist–Hospitalist Physician Practices Study

- Who: Clinical pharmacists.
- What: Cross-sectional survey of clinician pairs (clinical pharmacists and hospitalist physicians).
- Where: Inpatient settings.
- How: Complete online survey using REDCap in less than 1 hour.

The ACCP Practice-Based Research Network (PBRN) invites all clinical pharmacists who work on care teams with hospitalist physicians to consider participating in a survey-based research study. The survey will be administered to clinical pharmacist–hospitalist physician pairs; multiple clinical pharmacists from the same practice site may participate in the survey as long as unique clinicians (i.e., clinical pharmacist and hospitalist physician) are identified per pair. Study goals are to characterize clinical pharmacist–hospitalist physician collaborations and determine the challenges to successful relationships. Study results will be applied to either develop or refine existing best practices to effective use of these joint working relationships, given that both groups have the goals of optimizing patient care and reducing health care costs.

Survey Eligibility Criteria

1. Clinical pharmacist is interested in participating in the survey on behalf of his or her clinical pharmacist–hospitalist physician pair.
2. Clinical pharmacist practices in an inpatient setting.

3. Clinical pharmacist can identify at least two or three hospitalist physicians or providers from his or her practice site who are interested in participating in the survey.

To find out more about this study, including how you can participate, please contact our PBRN staff at pbrn@accp.com.

UPDATE ON PRN-RI LIAISONS

To establish and maintain relationships between the RI and each PRN, the RI recently encouraged PRNs to consider creating volunteer positions within their respective networks for individuals who wish to serve as liaisons between their membership and the RI. Broadly, these individuals will facilitate bidirectional communication of research-related ideas and activities between the PRN and the RI, including:

- Assisting the PRN with identifying opportunities for collaborative research with the ACCP PBRN,
- Disseminating information about and supporting PRN member applications to the RI’s funding and investigator training programs,
- Communicating PRN educational and infrastructure needs for research to the PBRN, and
- Communicating PRN research and programming ideas to help the RI better meet PRN needs through ACCP Annual Meeting programming/activities that support PRN member involvement in research.

Since announcing this opportunity, several PRNs have identified individuals to serve in these positions, and they routinely meet with RI staff to discuss collaborative opportunities. We are very encouraged by the enthusiastic response so far and look forward to future collaborations.

ACCP RI Announces 2017 Futures Grants Request for Applications

The ACCP Research Institute Futures Grants program invites student, trainee, and early-career ACCP members to apply for developmental research grants. Futures Grants may range from \$5000 to \$40,000, depending on applicant eligibility and the proposal’s requisite budget. Up to \$100,000 in mentored, developmental research awards will be granted through the Futures Grants program in 2017.

Before completing an application, applicants must complete the eligibility assessment. This assessment will guide each qualified applicant to either the Junior Investigator or the Student/Resident application. Completed applications are due by June 1, 2017. To access detailed instructions and complete the online

eligibility assessment and application, visit www.accpri.org/futuresapp. For all other questions, contact Carla Scarborough (cscarborough@accp.com).

Investigator Development Programs

Are you ready to accelerate your growth as a clinical pharmacy researcher? The Research Institute can meet your needs! Plan now to attend our next Mentored Research Investigator Training (MeRIT) or Focused Investigator Training (FIT) program June 26–30, 2017, on the campus of the University of Michigan College of Pharmacy.

MeRIT is an individualized, 2-year longitudinal program designed to mentor pharmacist-investigators from research idea through study design, IRB and funding application, data collection, results presentation, and manuscript submission.

FIT is an intensive 5-day grant enhancement and refinement program for experienced pharmacist-investigators pursuing NIH (National Institutes of Health) research funding. This proven combination of critical grant review, revision, and mentoring by experienced and funded faculty will maximize the competitiveness of your submission (or resubmission).

Applications for FIT and MeRIT will close March 31, 2017. For an informational brochure about the FIT and MeRIT programs or a copy of the application materials, please visit www.accpri.org/investigator/. Please contact Carla Scarborough (cscarborough@accp.com) with questions about either program.

WASHINGTON UPDATE

Washington Update

ACCP Testifies Before House Committee on Appropriations

On Wednesday, March 8, 2017, ACCP Associate Executive Director C. Edwin Webb, Pharm.D., MPH, FNAP, testified at a hearing in front of the House Committee on Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies.

The Appropriations Committee, together with its Senate counterpart, has jurisdiction over all government expenditures. The Subcommittee on Labor, Health and Human Services, and Education controls overall spending for the Department of Health and Human Services (HHS), including the entire Medicare program, the federal portion of the Medicaid program, and agencies including the Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), and National Institutes of Health (NIH).

In his testimony, Webb specifically urged the subcommittee to provide AHRQ with at least \$334 million in budget authority, consistent with current fiscal-year levels. AHRQ is the only federal agency with the sole purpose of evaluating and disseminating research that determines how to make care as effective, efficient, and affordable as possible. AHRQ supports research and communication programs that are perfectly aligned with ACCP's commitment to advancing a patient-centered, collaborative health care approach that delivers better care, smarter spending, and healthier people.

Webb went on to highlight the critical need to integrate coverage for comprehensive medication management (CMM) within the Medicare program as part of the overall effort to move all health care to a more value-based, collaborative, and efficient system.

The federal government is currently responsible for more than \$1 trillion per year in health care spending, and mandatory programs (including Medicare) are projected to overwhelm the entire federal budget. Webb therefore urged the subcommittee to provide adequate resources to ensure that health care delivery organizations, health providers, policy-makers, and the people they serve make informed choices about how to obtain the best care while addressing costs and protecting patient safety.

As part of this effort, ACCP has called on Congress to take action to meaningfully address problems associated with suboptimal and inefficient medication use and truly help patients “get the medications right” by promoting and advancing coverage for CMM services delivered under collaborative, patient-centered payment and delivery structures.

[Click here](#) to view a video of Webb's testimony.

[Click here](#) to read the written testimony in full.

ACA Repeal-Replace: Collapse of the American Health Care Act

H.R. 1628, the “[American Health Care Act](#)” (AHCA), released on March 6, 2017, was expected to serve as the legislative vehicle through which Republicans would fulfill longstanding pledges to repeal and replace the Affordable Care Act (ACA), also known as Obamacare.

Instead, by the evening of March 24, House Speaker Paul Ryan (R-WI)—who had personally championed the legislation—canceled a planned vote on the bill and informed President Donald Trump that in the absence of Democratic support, his party lacked the votes necessary to pass the plan.

What Did the Republican Plan Look Like?

Central to the challenges facing the GOP was the fact that despite its political posturing, the AHCA would not

have delivered a full repeal of the ACA. Certain key ACA provisions would have remained in place. In particular, the repeal bill retained several popular patient protections related to insurance coverage reform, such as the ACA's requirements that health plans:

- Cover preexisting conditions.
- Guarantee availability and renewability of coverage.
- Cover adult children up to age 26.
- Cap out-of-pocket expenditures.

The bill would also have protected the ACA's prohibitions against:

- Health status underwriting.
- Lifetime and annual limits.
- Discrimination on the basis of race, nationality, disability, age, or sex.

A Congressional Budget Office (CBO) analysis of the cost and social impact of the bill projected that if the AHCA were enacted, the number of uninsured would grow by 24 million by 2026 because of the elimination of the Medicaid expansion and the individual and employer coverage mandates. CBO found that the bill would reduce the budget deficit by \$337 billion over 2017–2026, through cutting Medicaid by \$880 billion and eliminating \$673 billion in ACA subsidies. In addition, the agency found that the bill would reduce taxes by \$883 billion. However, a large portion of these tax cuts would disproportionately benefit higher earners—almost \$300 billion in savings would have applied only to individuals earning over \$200,000 per year.

A Divided Republican Party

Immediately after the November 2016 elections, as Trump secured the presidency and the Republican Party retained control of both chambers of Congress, repeal of Obamacare seemed almost inevitable. On the campaign trail, Trump repeatedly stated that repeal was a top policy priority and a key reason he was running for president. Over the previous 6 years, congressional Republicans had voted to repeal President Barack Obama's signature legislation on more than 50 occasions. Yet when presented with the opportunity to finally deliver on these promises, Republicans were unable to coalesce around a unified strategy to move forward.

Despite full control of Congress, Republicans are deeply divided over how to replace Obamacare while Democrats remain fully united in their opposition to the repeal. Ultimately, it was the refusal of the members of the conservative Republican Freedom Caucus to support the proposal that led to its demise, based on their belief that the bill would keep too much of Obamacare intact. But there was also widespread concern among

more moderate Republicans that the AHCA would cause millions of Americans to lose health coverage without contributing in a truly significant way to deficit reduction.

At the same time, there were suggestions that Trump had blundered politically by putting pressure on Congress to fast-track passage of the legislation and issuing a "take-it-or-leave-it" ultimatum to the Freedom Caucus to support the AHCA or walk away. Members of the Freedom Caucus, in response, criticized the "binary choice" they faced in supporting either the AHCA or Obamacare.

What's Next?

It's clear that the collapse of the AHCA effort calls into question Trump's reputation as a skillful negotiator and dealmaker and casts doubts over the congressional Republicans' ability to build consensus within an ideologically divided party. But already, tentative discussions are emerging on Capitol Hill around legislative concepts that could possibly yield broad Republican support. Most Republicans will admit that strategically, mistakes were made in their approach to the repeal-and-replace process. Yet the party remains unequivocal in its opposition to Obamacare. As the White House acknowledges that the health care reform process is far more complicated than it anticipated, there is a glimmer of optimism that a renewed effort to replace Obamacare will be more thoughtful, consensus-driven, and even, possibly, bipartisan.

ACCP Board of Regents Approves Position Statement: "Optimizing Specialty Drug Use"

National spending on prescription medications has steadily—and significantly—increased. Although advanced science and technology have led to new therapies with tremendous promise, their associated cost to providers, patients, and payers in many cases limits access to these therapies across the spectrum of health care delivery. Moreover, specialty medications (i.e., medications with a total average cost greater than \$1000 per prescription or an average daily cost greater than \$33 per day) account for a disproportionate share of these costs.

The "right prescription for the right patient" has always reflected one of pharmacists' fundamental commitments to their patients. However, its meaning must evolve to "getting the medications right" for all patients by incorporating a commitment to ensuring the selection of the right patients for such expensive therapies. Combining comprehensive medication management (CMM) with value-based pricing strategies promises more rational and economical use of specialty medications by optimizing their use for patients and health systems.

In response to this issue, the ACCP Board of Regents approved a new position statement, "Optimizing Specialty Drug Use," in February during the 2017 Updates in Therapeutics® meeting in Jacksonville, Florida. This

statement is intended to express ACCP's position on optimal specialty drug use and to emphasize that CMM is necessary to achieve optimal specialty medication use in order to ensure the best possible outcomes for patients and the health care system.

Please review the pre-publication version of the statement and contribute to our dialogue about the importance of clinical pharmacists' work in "getting the medications right" in the context of specialty drug use.

[Click here](#) to read the statement in full.

ACCP-PAC Contributions Support Bipartisan Health Care Leaders in Congress

The partisan divide in Washington has reached unprecedented levels. Amid this sometimes toxic political environment, ACCP is targeting true health care leaders from both parties who are willing to work with colleagues across the aisle to enact health care legislation focused on team-based, patient-centered care that measures and rewards quality and outcomes.

However, these moderate, bipartisan legislators will inevitably face primary challenges from the fringes of their parties. ACCP must provide support for such leaders in order to ensure they remain in Washington and continue to advance policies that meaningfully address the health care issues our nation currently faces.

With the Affordable Care Act (ACA) repeal and replace now under way and entitlement reform (including potentially significant changes to Medicare payment and delivery structure) on the horizon, a well-funded PAC is essential.

Only ACCP members are eligible to contribute to the PAC and allow us to make these vital political contributions. With its more than 18,000 ACCP members, ACCP is in a position to become one of the most prominent pharmacy PACs in Washington. To do this, we need the widespread support of our membership.

If each ACCP member contributed just \$25, ACCP-PAC would raise over \$350,000. All ACCP members should consider donating at least \$25 to ACCP-PAC. [CLICK HERE](#) to support your PAC today!

Contact Us! For more information on any of ACCP's advocacy efforts, please contact:

John K. McGlew
Director, Government Affairs
American College of Clinical Pharmacy
1455 Pennsylvania Ave. Northwest
Suite 400
Washington, DC 20004-1017
(202) 621-1820
jmcglew@accp.com

STUDENT INITIATIVES UPDATE

ACCP Student Chapter Growth

With the growing interest in clinical pharmacy, ACCP expanded opportunities for student involvement in the College by formally recognizing student chapters in October 2013. Since then, 80 student chapters have been formed.

Benefits of Student Membership

Students can benefit from ACCP membership in many ways, including:

- Leadership development experiences (as student liaisons and as members of the National Student Network Advisory Committee);
- Options to explore clinical pharmacy specialties (by taking advantage of complimentary student membership in up to one PRN);
- Opportunities to expand and showcase their knowledge (through scientific poster presentations and the Clinical Pharmacy Challenge); and
- Career development guidance (through the CV Review Service, the "Emerge from the Crowd: How to Become a Standout Residency Candidate" sessions, and career development programming at national meetings).

Creating a student chapter is a great way to help pharmacy students learn about clinical pharmacy and get involved in ACCP. Any ACCP college of pharmacy faculty liaison can establish a formally recognized student chapter by submitting an official chapter application. If the application is approved, the liaison will be invited to serve as the chapter's primary faculty adviser. To obtain complete information on establishing a student chapter and to download a New ACCP Chapter Application, please visit www.accp.com/stunet/studentliaisons.aspx.

For more information about student chapters, e-mail us at membership@accp.com.

2017 ACCP Student Chapter Awards—Applications Due June 30

ACCP recognizes two awards for Student Chapter members: the Outstanding Student Chapter and the Outstanding Student Chapter Member. These honors will be awarded annually. Application for each award is submitted as part of the *Annual Chapter Report* and is due June 30, 2017. A description of each award follows.

Outstanding Student Chapter Award

This award recognizes the ACCP student chapter that has exemplified strength in leadership, dedication in patient care, and passion for professional development through

its activities and membership. The chapter's activities should address ACCP's core values of extending the frontiers of clinical pharmacy and promoting dedication to excellence in patient care, research, and education. A key component of all the core values is the clinical pharmacist's ability to work collaboratively within the health care environment. Each chapter must demonstrate its ability to work with other health disciplines.

An announcement will be featured on the ACCP website, and an article highlighting the winning chapter's accomplishments will be published in *StuNews* and the *ACCP Report*. A commemorative plaque and \$1000 in cash will be awarded to the winning chapter. The faculty liaison/adviser and one appointed student liaison from the winning chapter will receive complimentary full 2017 ACCP Annual Meeting registrations, and each will receive a \$250 travel stipend to attend.

Members of student chapters who wish to apply for the award will complete an application form as part of their end-of-year report, due June 30. As part of the application process, each chapter is required to submit a rationale statement (250 words or less) outlining the plan for using the \$1000 in award funds, should it be selected as the winner.

Outstanding Student Chapter Member

This award recognizes a student who has enhanced student involvement from his or her ACCP chapter at the local, state, or national level and who has expanded ACCP's presence through community engagement, education promotion, research opportunities, and/or professional stewardship. The activities of the student selected should address ACCP's core values of extending the frontiers of clinical pharmacy and promoting dedication to excellence in patient care, research, and education.

Each chapter award recipient will receive a certificate suitable for framing and recognition in an *ACCP Report* article, a *StuNews* article, and the *Annual Meeting News*. In addition, student award winners in attendance at the award-year ACCP Annual Meeting will be recognized during the Clinical Pharmacy Challenge semifinal round of competition. Each recognized student chapter will select its recipient for Outstanding Student Chapter annually and submit the winner's name to the ACCP national office as part of its year-end report, due June 30.

ACCP SNAC Now Accepting Applications for 2017–2018

Initiated as a working group in 2006, the National Student Network Advisory (SNAC) group became a standing committee of the College in 2007. Members are appointed by the ACCP president-elect. The present committee serves in an advisory capacity to the ACCP Board of

Regents and staff, providing feedback and assistance in developing new programs and services for students. Student members who are interested in serving on the ACCP SNAC, either as a member-at-large or in a leadership role, may apply for appointment. All applicants must submit a CV, personal essay, and letter of recommendation from a professor, preceptor, or academic dean or his or her designee. Application for appointment to the 2017–2018 SNAC is available online. Applications are due June 16, 2017.

PGT UPDATE

Postgraduate Trainee Update

All resident, fellow, and graduate student members of ACCP currently receive a monthly electronic newsletter, *Experts in Training*. The readers would like to thank all the PRNs, residency programs, and clinical pharmacists who have contributed to the publication. You may view the archives [here](#). For topics you'd like to see covered in future editions, submit your ideas to ksims@accp.com.

ACCP will continue to offer resident/fellow-specific educational programming at the 2017 ACCP Annual Meeting. Residents and fellows will also be able to speak to recruiters and preview early practitioner positions in the new Professional Placement Forum. Consider representing your institution's residency, fellowship, or new practitioner position at the 2017 ACCP Annual Meeting Professional Placement Forum.

In addition to the live programming, ACCP offers two, free, live webinars each year for residents and fellows. The [webinars](#), archived on the ACCP website, each provide 1.0 contact hour of continuing education.

Fifty-one postgraduate trainee members of ACCP are currently participating in the 2016–2017 Mentoring Program. Mentors are ACCP members who have at least 5 years of professional experience and have volunteered to participate in the program. Mentor/mentee pairs are encouraged to correspond at least monthly and are provided with timely topics of discussion. A call for mentors goes out each year in August.

The College is currently accepting applications for all positions on the 2016–2017 National Resident Advisory Committee. The committee is a working group composed of resident, fellow, or graduate student members of ACCP. Applications for chair, vice chair, and member-at-large positions are due by June 16, 2017.

All resident and fellow members are encouraged to follow #ACCPpostgrads on ACCP social media accounts.

PRN MEMBERSHIP TOTALS

Practice and Research Network	Total Members
Ambulatory Care PRN (AMBU)	2327
Adult Medicine PRN (AMED)	1204
Cardiology PRN (CARD)	1383
Central Nervous System PRN (CNSY)	263
Clinical Administration PRN (CADM)	460
Critical Care PRN (CRIT)	2333
Drug Information PRN (DINF)	351
Education and Training PRN (EDTR)	599
Emergency Medicine PRN (EMED)	999
Endocrine and Metabolism PRN (ENDO)	330
Geriatrics PRN (GERI)	404
GI/Liver/Nutrition PRN (GILN)	235
Global Health PRN (GLBL)	190
Health Outcomes PRN (OCEC)	227
Hematology/Oncology PRN (HMON)	
HIV PRN (HIV)	267
Immunology/Transplantation PRN (IMTR)	548
Infectious Diseases PRN (INFD)	2314
Nephrology PRN (NEPH)	214
Pain and Palliative Care PRN (PAIN)	360
Pediatrics PRN (PEDI)	1061
Perioperative Care PRN (PERI)	99
Pharmaceutical Industry PRN (INDU)	
Pharmacokinetics/Pharmacodynamics/Pharmacogenomics PRN (PKPD)	344
Women's Health PRN (WOMN)	292
TOTAL:	18,106

PRN CONTACT INFORMATION

For more information about a specific PRN, please contact the PRN's incoming chair, identified as follows.

PNR TITLE	PNR CONTACT
Adult Medicine	<u>Sarah L. Anderson, Pharm.D., BCPS</u>
Ambulatory Care	<u>Daniel M. Riche, Pharm.D., BCPS, CDE</u>
Cardiology	<u>Toni L. Ripley, Pharm.D., FCCP, BCPS</u>
Central Nervous System	<u>Jeffrey Bishop, Pharm.D., M.S., BCPP</u>
Clinical Administration	<u>Angela B. Smith, Pharm.D., BCPS, MHA</u>
Critical Care	<u>Pamela L. Smithburger, Pharm.D., M.S., BCPS</u>
Drug Information	<u>Dianne W. Ma, Pharm.D., BCPS</u>
Education and Training	<u>Joshua Caballero, Pharm.D., BCPP</u>
Emergency Medicine	<u>Asad Patanwala, Pharm.D., BCPS</u>
Endocrine and Metabolism	<u>Amy Calabrese Donihi, Pharm.D., BCPS</u>
Geriatrics	<u>Amber N. McLendon, Pharm.D., BCPS</u>
GI/Liver/Nutrition	<u>Michael A. Smith, Pharm.D., BCPS</u>
Global Health	<u>Renee M. Holder, Pharm.D.</u>
Health Outcomes	<u>Karen Smith, RPh, Ph.D.</u>
Hematology/Oncology	<u>David L. DeRemer, Pharm.D., BCOP</u>
HIV	<u>Melissa Badowski, Pharm.D.</u>
Immunology/Transplantation	<u>Christopher R. Ensor, Pharm.D., BCPS</u>
Infectious Diseases	<u>Christopher M. Bland, Pharm.D., FIDSA, BCPS</u>
Nephrology	<u>Mary Vila, Pharm.D.</u>
Pain and Palliative Care	<u>Jane E. Pawasauskas, Pharm.D., BCPS</u>
Pediatrics	<u>Christina Cox, Pharm.D.</u>
Perioperative Care	<u>Stacey Bortlik (Moultrie), Pharm.D.</u>
Pharmaceutical Industry	<u>David R. Luke, Pharm.D., BScPharm, FCCP</u>
Pharmacokinetics/Pharmacodynamics/Pharmacogenetics	<u>Keith A. Moore, Pharm.D., BCPS</u>
Women's Health	<u>Brooke L. Griffin, Pharm.D.</u>